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ABSTRACT 
 Myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular 
dystrophy, is an incurable neuromuscular disease. DM1 is caused by an expansion of the CTG 
repeat, whose RNA transcript sequesters the MBNL1 protein into nuclear foci, leading to the 
misregulation of various pre-mRNAs.  
 Based on a published x-ray structure of a r(CUG)6 duplex, a benzamidinium ligand was 
rationally designed and found to selectively bind rCUG repeats and inhibit the MBNL1-rCUGexp 
interaction with a low micro-molar inhibition potency. Thus, this bisamidinium RNA groove 
binder represented one of the most promising lead compounds for DM1 treatment. The 
development of the bisamidinium analogs containing functional substituents will be discussed in 
Chapter 2. 
Chapter 3 describes the development of a bisamidinium dimeric ligand as a possible 
compound for the treatment of DM1. This ligand reveals both the promise and challenge for the 
small molecule approach. The agent is a potent inhibitor of the MBNL1-rCUGexp both in vitro 
and in DM1 model cells, and is able to improve two distinct disease phenotypes in a DM1 
Drosophila model. However, its relatively low maximum tolerated dose in mice and limited cell 
uptake provide insights into directions for future development. 
In addition, a powerful selection method that uses the target DNA or RNA to select their 
own binders will be discussed in Chapter 4. Compounds discovered using this method are able to 
undergo the alkyne-azide cycloaddition on the target DNA and RNA. The selectivity of these 
compounds along with their click products to other DNA/RNA sequences can also be readily 
accessed. The click products formed have better efficacy  and can be used as multi-target agents. 
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CHAPTER 1 
INTRODUCTION 
1.1 Overview of Myotonic Dystrophy 
Myotonic dystrophy (Dystrophia Myotonia, DM) is an autosomal dominant 
neuromuscular disorder, which affects 2−14 in 100,000 people worldwide.1 DM patients have a 
wide range of symptoms, including muscle weakness (myopathy), trouble relaxing certain 
muscles (myotonia), progressive muscle wasting (atrophy), cataracts, cardiac defects, and 
insulin-dependent diabetes.2,3 Myotonic dystrophy exists in two major types: type 1 (DM1), the 
most common form with a global prevalence of 1 per 8,000 people, and type 2 (DM2) with a 
high prevalence in Europe.4 
1.2 Pathogenic Mechanisms of Myotonic Dystrophy Type 1 
DM1 is caused by a progressive expansion of the trinucleotide CTG repeat (dCTGexp) in 
the 3'-untranslated region of the dystrophia myotonica-protein kinase (DMPK) gene on 
chromosome 19q13.3.5,6 Healthy individuals have a low number of CTG repeats, fewer than 35, 
whereas the number of repeats for a DM1 patient can range from 50 to thousands.6 The length of 
CTG repeats directly correlates with the symptom severity and the age of onset.7 Previously, 
there were three possible pathogenic mechanisms considered for DM1:8 1) haploinsufficiency of 
DMPK,9 2) decreased expression of neighboring genes, including SIX5 and DMAHP,10,11 and 3) 
a gain-of-function for the expanded RNA transcript (rCUGexp).2 Recent findings have provided 
evidence against the first two hypotheses, leaving the RNA gain-of-function as the most probable 
mechanism for therapeutic intervention.2,12	
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The RNA gain-of-function model involves the sequestration of the muscleblind (MBNL) 
protein family of splicing regulators by expanded rCUG repeats (rCUGexp) (Figure 1).13,14 In 
DM1 cells, the co-localization of MBNL1 protein and rCUG repeats in nucleus results in the 
formation of nuclear foci.15 It was found that more than 80% of aberrant alternative splicing 
events are directly related to the sequestration of MBNL1 by rCUGexp in a DM1 mouse model.16 
Many of the symptoms of DM1 result from these mis-splicing events.17 For example, myotonia, 
insulin resistance, cardiac abnormalities, muscle weakness are caused by the aberrant splicing of 
chloride channel 1 (ClC-1),18 insulin receptor (IR),19 cardiac troponin T (cTNT),8 and 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 1 (SERCA1),20 respectively. 
In contrast to MBNL1 loss-of-function, the expression of CUG-BP1 and ETR-3-like 
factor 1 (CELF1) is up-regulated in DM1 heart and skeletal muscle tissues and a DM1 mouse 
model.21 The process of up-regulation is attributed to the protein kinase C-activated 
 
Figure 1. Pathogenic mechanisms of DM1. 
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hyperphosphorylation and stabilization of CUG-BP1.22 Unlike MBNL1, CUG-BP1 binds short, 
single-stranded rCUG repeats, and does not co-localize with the toxic RNA to form nuclear 
foci.15 In 2005, Cooper and coworkers found that transgenic mice overexpress 4−6 fold above 
the endogenous level of CUG-BP1 and have aberrant splicing of cTNT, Mtmr1, and ClC-1 in 
heart and skeletal muscle tissues, suggesting the increase in CUG-BP1 level as one of the DM1 
pathogenesis.21  
Apart from these two disease mechanisms, Kalsotra et al. found that the significant 
reduction of MEF2 protein level results in altered miRNA and mRNA expression in heart 
tissue.23 Recently, Ranum showed that both rCAG and rCUG repeats can undergo the repeat-
associated non-ATG (RAN) translation, producing six toxic homopolymeric proteins.24  
1.3 Therapeutic Approaches to the Treatment of Myotonic Dystrophy Type 1 
Recent studies suggest that inhibiting the formation of the MBNL1-rCUGexp complex 
could be a potential therapeutic approach for DM1.3 In 2003, Swanson and coworkers showed 
that a muscleblind knockout mouse model (Mbnl1Δ3/Δ3) exhibited phenotypic features associated 
with DM1, such as myotonia, cataract defect, and abnormal splicing of ClC-1, cTNT.25 
Conversely, the overexpression of MBNL1 in HSALR mice using adeno-associated virus 
mediated transduction was found to relieve myotonia and correct the missplicing of ClC-1, 
TNNT3, and SERCA1 to nearly wild-type levels after 23 weeks.26 Three possible approaches to 
the inhibition of MBNL1-rCUGexp complex include (1) targeting RNA to displace MBNL1 
protein, (2) targeting DNA to reduce rCUG transcript levels or suppress the repeat expansion, 
and (3) upregulating MBNL1 level. 
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Targeting RNA. RNA has become the central target in part because of the availability of 
high-resolution structures of rCUG repeats.27,28 A number of RNA binding ligands, including 
antisense oligonucleotides and small molecules, have been developed over the past decade. Most 
of small molecule inhibitors of MBNL1 binding were discovered from screening methods, such 
as a pentamidine29 from a library of 26 nucleic acid binding molecules, and a naphthyridine-
containing compound30 from the NIH Chemical Genomics Center (Figure 2). These compounds 
exhibit promising therapeutic properties, including dissolving the MBNL1-rCUGexp nuclear foci 
and correcting splicing defects in DM1 model cells and mice. To improve the binding affinity of 
small molecules toward rCUG repeats and inhibition potency of MBNL1 complex formation, 
Disney and co-workers reported modularly assembled ligands by attaching several 
bisbenzimidazole Hoechst 33258 or kanamycin units on a peptoid backbone.31,32 Moreover, upon 
photolysis, a rCUG binder conjugated with an N-hydroxypyridine-2(1H)-thione moiety is 
capable of producing hydroxyl radicals and cleaving rCUG repeats specifically.33 In addition, a 
compound that binds and covalently conjugates to rCUG repeats was found to exhibit improved 
inhibition potency.34 Although many small molecules have promising therapeutic properties, 
none have advanced into clinical trials. However, a 2’-O-methyl-phosphorothioate modified-
 
Figure 2. Possible small molecules for treatment of DM1. 
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(CAG)7 oligonucleotide developed by Thornton was shown to significantly reduce the toxic 
rCUG level in DM1 mouse models, and is currently being tested in phase 2 clinical trials.35 
Transcription inhibition of dCTG repeats. Recently, this approach has emerged as an 
alternative therapeutic strategy for DM1, as it may lead to the reduction of toxic rCUGexp level.36 
In 2015, Berglund and coworkers reported that actinomycin D, an FDA-approved 
chemotherapeutic agent, is capable of reducing the rCUG transcript levels in DM1 model cells 
and mice at low nanomolar concentration.37 In addition, a pyrrole-imidazole polyamide-
chlorambucil conjugate was shown to induce the DNA alkylation of the target sequence and 
inhibit transcription of the CAG-CTG repeat.38 However, the potential for expansion or 
contraction of the repeat regions upon binding to dCTG remains unknown. 
Overexpression of MBNL1 protein. Another approach to the treatment of DM1 is 
overexpression of MBNL1. Recently, it was found that treatment with phenylbutazone, a 
nonsteroidal anti-inflammatory drug, resulted in the unregulated expression of MBNL1 
myoblasts and DM1 mouse model, leading to the improvement of abnormal splicing events, 
muscle weakness, and muscle pathology.39  
1.4 Development of Small Molecule Agents in the Zimmerman Group 
Based on the available structures of rCUG repeats and using a rational design method, we 
have developed several small molecules that bind rCUG repeats and inhibit its interaction with 
MBNL1 protein (Figure 3, Table 1). It is known that rCUG repeats can form stable stem loop 
structures with U-U mismatches flanked by G-C and C-G base pairs.27,28 Compounds 1−4 
contain triaminotriazine rings that can serve as a Janus-wedge recognition unit capable of 
forming hydrogen bonds to the uracil-uracil (U-U) and thymine-thymine (T-T) mismatches.40 
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Ligand 1 is a melamine-acridine conjugate, in which the acridine intercalator helps drive 
binding by slipping between the melamine ring and a G-C base pair, while the triaminotriazine 
ring serves as the recognition unit.41 Compound 1 is highly selective for T-T and U-U 
mismatches. It was suggested that the triaminotriazine ring in compound 1 recognizes the U-U 
mismatch in the RNA major groove, whereas it forms hydrogen bonds to the T-T mismatch in 
the DNA minor groove (Figure 4).40 Compound 1 was one of the first small molecule inhibitors 
of the MNBL1-rCUGexp complex to be reported in the literature. We previously discovered that 
the acridine-based ligands and MBNL1 can form a ternary complex with rCUG repeats, 
indicating that inhibition may be noncompetitive.42 However, compound 1 suffers from the poor 
water solubility, an inability to penetrate the nuclear membrane, and high toxicity. Therefore, the 
efficacy of 1 in DM1 model cells was not studied. 
 
Figure 3. Five compounds developed in the Zimmerman group.  
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 To overcome these issues, Dr. Amin H. Jahromi prepared ligand 2 by attaching a 
polyamine chain to the acridine moiety.43 In DM1 model cells, treatment of 2 at 75 µM for 
48 h resulted in a ca. 86% reduction of cells containing MBNL1-r(CUG)960 foci. It was also 
found that ligand 2 is capable of rescuing 40% of the IR splicing defect. In addition, compound 
3, discovered from a small library of bivalent ligands containing different polyamine or 
polyether linkers, shows significantly improved binding affinity to rCUG repeats, and inhibition 
 
Figure 4. Proposed recognition of the triaminotriazine ring to (A) U-U mismatch in the RNA major 
groove and (B) T-T mismatch in the DNA minor groove. (Figure was adapted from Ref	40) 
Table 1. Biological activities of ligands 1−5. Dissociation constants (KD) determined by (a) Isothermal 
Titration Calorimetry (ITC) and (b) reverse fluorescence titration of TAMRA-r(CUG)6 to ligands. IC50 
for the inhibition of MBNL1-r(CUG)12 determined by (c) electrophoretic mobility shift assay (EMSA) 
and (d) surface plasmon resonance (SPR). KI value was calculated using the equation: KI = IC50 × KD / 
[protein]total, where KD is the dissociation constant of the MBNL1–RNA complex. Toxicity to (e) HeLa 
cells. 
Comp. 
Binding to CUG 
KD, µM 
Inhibition of MBNL1-
CUG 
Cytotoxicitye 
IC50, µM 
Foci 
dispersion 
Splicing 
reversal 
IC50, µM KI, µM 
1 0.43 ± 0.11a, r(CUG)4 46 ± 7c 7 ± 1 N/A N/A N/A 
2 N/A 15 ± 2d N/A <10, 72 h ✓ ✓ 
3 0.32 ± 0.02b, r(CUG)6 1.1 ± 0.1d N/A <50, 24 h ✓ N/A 
4 8 ± 2a, r(CUG)12 115 ± 14c 8 ± 2 >100, 72 h ✓ ✓ 
5 N/A 61 ± 15c 15 ± 3 ~24, 72 h N/A N/A 	
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of MBNL1-rCUGexp complex compared to ligand 1.44 
In addition to the triaminotriazine-acridine conjugate, Dr. Chun-Ho Wong rationally 
designed ligand 4 as a rCUG major groove binder.45 Compound 4 contains two triaminotriazine 
recognition units, each linked to a bisamidinium benzene by a four methylene linker. Ligand 4 
has a number of features that make it a promising lead candidate, including a low micromolar 
binding affinity (KD = 8 ± 2 µM) to r(CUG)12 and a modest inhibition of the MBNL1-r(CUG)12 
complex (KI = 8 ± 2 µM). In addition, ligand 4 is water soluble, and non-toxic to HeLa cells up 
to 100 µM after 3-day incubation. In DM1 model cells, the nuclear foci formed by rCUG and 
MBNL1 was significantly reduced upon treatment of 4 at 100 µM for 48 h. Furthermore, the mis-
splicing of cTNT and IR pre-mRNAs were partially restored. Ligand 4 was also found to reverse 
the rCUG-induced rough and glossy eye phenotypes in a DM1 Drosophila model. 	
Using fluorescence anisotropy, Eric (Yen Jun) Ho discovered compound 5 from the 
Diversity Set III of the National Cancer Institute compound library as a low micromolar inhibitor 
of the MBNL1-rCUGexp. However, preliminary results showed that ligand 5 exhibits weak 
interactions with rCUG and MBNL1, and a low micromolar binding affinity to a CTG repeat.  
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CHAPTER 2 
DEVELOPMENT OF THE BISAMIDINIUM ANALOGS1 
2.1 Introduction to the Bisamidinium Ligand 
Bisamidinium-based ligand 4 has many promising therapeutic properties and was 
considered as a key lead compound in this work. Ligand 4 exhibits modest binding affinity 
toward rCUGexp (KD = 8 ± 2 µM) and inhibition of MBNL1-rCUGexp (KI = 8 ± 2 µM).45 With 
high water solubility, and low cytotoxicity in HeLa cells, the efficacy of 4 in DM1 model cells 
was studied, showing that 4 was able to dissolve nuclear foci and partially correct splicing 
defects. Therefore, for further development of 4, its binding mode to rCUG repeats should be 
elucidated. Herein, I provide some preliminary binding data, and uncover a point of modification 
on 4 where substituents can be placed without affecting the binding affinity. This work provides 
a foundation for future developments of more efficacious melamine-bisamidinium ligands. 
2.2 Binding of the Bisamidinium Ligand to rCUG Repeats  
The rational design of ligand 4 was based on the reported NMR structure of the complex 
between a frame-shifting bisamidinium stimulator ligand DB213 and its HIV-1 frameshift site 
(FS) RNA stem-loop target (Figure 5a).46 It was suggested that amidinium groups form hydrogen 																																																								
1 Some of the material in this chapter was adapted from the following publications: 
Luu, L. M.; Lee, J.; Nguyen, L.; Vergara, J. I.; Zimmerman, S. C. A Fragment-Based, Multi-target Drug Discovery 
Approach for Both DNA and RNA Targets Using a Template-Assisted Selection. (Manuscript in preparation) 
Luu, L. M.; Nguyen, L.; Peng, S.; Lee, J.; Lee, H. Y.; Wong, C.-H.; Hergenrother, P. J.; Chan, H. Y. E.; 
Zimmerman, S. C. ChemMedChem 2016, 11, 1428–1435. 
Nguyen, L.; Luu, L. M.; Peng, S.; Serrano, J. F.; Chan, H. Y. E.; Zimmerman, S. C. J. Am. Chem. Soc. 2015, 137, 
14180–14189. 
Wong, C.-H.; Nguyen, L.; Peh, J.; Luu, L. M.; Sanchez, J. S.; Richardson, S. L.; Tuccinardi, T.; Tsoi, H.; Chan, W. 
Y.; Chan, H. Y. E.; Baranger, A. M.; Hergenrother, P. J.; Zimmerman, S. C. J. Am. Chem. Soc. 2014, 136, 6355–
6361.  
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bonds with the phosphate oxygens on opposite strands of the HIV-1 FS RNA stemloop (Figure 
5b).46 An overlay of the r(CUG)12 x-ray structure and the NMR-determined HIV-1 FS RNA 
structure showed striking similarities (Figure 5c), suggesting that the bisamidinium moiety could 
potentially serve as a rCUG major groove binder. Thus, the bisamidinium unit of 4 was designed 
to cover the central CUG with two triaminotriazine rings to recognize the two adjacent U-U 
mismatches (Figure 5d).45 We anticipated that the 1,3 U-U mismatches are essential for the 
recognition of ligand 4, whereas the internal U-U mismatch would have no impact on the binding 
affinity of 4 toward A and B.  
Isothermal titration calorimetry (ITC) was employed to study the binding of 4 to different 
rCUG oligonucleotide sequences. Thermodynamic parameters and binding stoichiometry can be 
derived from ITC experiments, allowing the users to gain insight into the binding mode of the 
designed ligands.47 Although a large quantity of material is needed for a single experiment, this 
 
Figure 5. Rational design of ligand 4. a) Schematic diagram and b) Illustration of the DB213-HIV-1 FS 
RNA complex. c) An overlay of the r(CUG)6 x-ray structure (blue, PDB: 3GM7) and the NMR-
determined HIV-1 FS RNA structure (grey, PDB: 2L94). (d) Proposed binding of compound 4 to rCUG 
repeats. (The image was adapted from Ref 45 and 46 with minor changes) 
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method does not require labeling of either the small molecule or RNA.  
RNA constructs A and B, containing three and two U-U mismatches, respectively, were 
employed to investigate the binding mode of 4 with rCUG repeats (Figure 6). These sequences 
contain a UUCG tetraloop to promote the hairpin formation.48 Before the ITC measurement was 
performed, the RNA sequences were refolded by heating the RNA solution at 95 °C for 5 min 
and cooling to room temperature for 2 h. After refolding, both sequences existed as a single 
conformation as indicated by native gel. The binding of 4 to rCUG repeats was studied at 25 °C 
at pH 7.0 (MOPS 20 mM, NaCl 150 mM).  
It was found that no binding isotherm was detected for the interaction of 4 with construct 
B, whereas a low micromolar binding affinity towards construct A was observed (Figure 6). A 
two sequential binding model was employed to fit the binding isotherm of 4 with construct A. 
The strongest binding event with a KD value of 1.4 µM is exothermic and entropy driven. The 
second interaction (KD = 103 µM) is 74-fold weaker than the first binding event. Although, the 
interaction of 4 with construct B was also characterized by two sequential binding events with 
the KD values of 36 and 372 µM, a negligible amount of heat was generated from the titration, 
signifying a weak interaction of 4 to construct B. Because the equivalence point was not clearly 
observed from the isotherm, the binding stoichiometry was not determined. Although increasing 
concentrations of both ligand and RNA could resolve this problem, the high cost of RNA makes 
it economically impractical. 
This ITC study demonstrates the importance of the middle U-U mismatch in the 
interaction of 4 to CUG repeats. However, one may argue that two consecutive U-U mismatches 
provide a sufficient binding site for ligand 4, given by the weak binding of 4 to construct B, 
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where the middle U-U mismatch is replaced by a G-C base. On the other hand, the internal 
mismatch may be more accessible for the bisamidinium moiety than the fully paired bases. 
Therefore, binding of 4 toward construct C and D would shed light on this question (Figure 6). 
	2.3 Synthesis and Binding Study of Bisamidinium Analogs 
The two most important considerations in designing the bisamidinium analogs include 
their synthetic accessibility and their ability to span adjacent binding sites without disrupting the 
primary interactions with rCUG repeats. The substituted analogues of dicyanobenzene and 1,4-
diaminobutane are quite limited in availability, while unsymmetrically substituted 
triaminotrazines are readily synthetically accessible. Thus, the logical functionalization point was 
the triaminotriazine amino group of 4. The key question was whether N-substitution of one or 
both of the triaminotriazine units of 4 would affect its ability to bind rCUGexp. Previously, we 
      
Figure 6. ITC binding curves represented for the interactions of ligand 4 with construct A (left) and 
construct B (right). 
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showed that methylation of amino groups in the triaminotriazine-acridine ligand 1 may have a 
profound effect on both affinity and selectivity.40 To address this issue in the bisamidinium 
ligands, compound 6a−c were prepared (Figure 7 and Scheme 1), and their binding affinity to 
rCUG repeats was determined.  
The preparation of 6a–c containing two alkyne or azide groups was based on the 
originally proposed synthetic route of ligand 4 (Scheme 1).45 The triazine 7 was treated with 
propargylamine 8a, 3-azido-propylamine 8b, or 3-azido-propylamine 8c at room temperature, 
affording 9a–c in good yields. The reaction of 9a–c with an excessive amount of 1,4-
diaminobutane was refluxed at 90 °C to give compounds 11a–c, which was reacted with bis-
imidate ester 12 in anhydrous ethanol to afford ligands 6a–c in moderate to high yields. 
Compounds 6a–c were purified by either silica gel or C18 column chromatography. The 
purification yielded tetrahydrochloride salts of 6a–c with a purity of at least 95% as indicated by 
Scheme 1. Synthesis of 6a−b. 
 
 
Figure 7. Structures of compounds 6a−b. 
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NMR and HPLC. 
It was discovered from a single ITC experiment that the binding affinity toward r(CUG)12 
of compound 6a (KD = 7.7 µM) and 6c (KD = 4.8 µM) were similar to that of 4 (KD = 8 ± 2 µM) 
(Figure 8).45 They also exhibit similar binding isotherms. This finding supports the proposed 
binding mode of the triaminotriazine to the U-U mismatch where one of the remaining NH2 
groups can be mono-alkylated.40 This finding enabled the rapid development of a wide range of 
functional analogs of ligand 4 using the [3+2] copper-assisted alkyne-azide cycloaddition of 6a 
and 6c. 
This binding study also suggests that substitutions on the triaminotriazine rings would not 
		  	  
Figure 8. ITC binding isotherm to r(CUG)12 of 6a (left) and 6c (right). The binding isotherms were 
fitted with the 3 sequential binding sites model. The heat generated at the end of the titration may result 
from the dilution of the RNA storage buffer in the RNA solution as the ligand solution was added. 
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affect the binding affinity of the bisamidinium ligands. In fact, compound 15, prepared as 
described in Scheme 2, showed comparable binding affinity to r(CUG)12.49 Remarkably, Dr. Lien 
Nguyen found that 15 is able to 1) bind dCTG repeats and inhibit its transcription, 2) bind rCUG 
repeats and inhibit MBNL1-rCUGexp complex, and 3) degrade rCUG repeats.49 In chapter 3, 
development and evaluation of the potent bisamidinium bivalent ligands will be described. 
2.4 Conclusions and Outlook 
In conclusion, the binding study of 4 by ITC suggests that three consecutive U-U 
mismatches provide a sufficient binding site for the bisamidinium-based ligand 4. Although, 
more evidence could be obtained to further elucidate the binding mode of 4 toward rCUG repeats 
and advance the development of bisamidinium ligands, thus far we found that the 
triaminotriazine ring can be functionalized with different substituents with minimal structural 
and binding perturbation.  This finding has allowed us to develop the bisamidinium ligands for 
different purposes, including multi-target agents and multivalent ligands. 
Scheme 2. Synthesis of ligand 15. 
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2.5 Materials and Methods 
2.5.1 Synthesis 
All reactions were carried out under a dry N2 atmosphere with oven-dried (115 °C) 
glassware. All solvents and reagents were of reagent quality, purchased commercially, and used 
without further purification. Reactions were monitored by thin layer chromatography using EMD 
pre-coated silica gel 60 F254 plates. Flash chromatography was performed using Silicycle 
SiliaFlash P60 (230–400 mesh) silica gel. 1H and 13C NMR spectra were recorded on a 500 MHz 
Varian Unity Inova spectrometer. Chemical shifts and coupling constants (J) were reported in 
ppm and Hertz, respectively. Electrospray ionization mass spectra (LR ESI-MS) were obtained 
by the Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois at 
Urbana-Champaign. High performance liquid chromatography (HPLC) was performed using a 
Dynamax SD-200 system with a UV detector set at 260 nm and a DENALI C18 Vydac column 
(250 × 10 mm) with a dual solvent system of 0.1% TFA in H2O (Solvent A) and 0.1% TFA in 
MeOH (Solvent B). 
         
    Compound 9a: To a suspension of 1.5 g (9.1 mmol) of 7, and 1.6 mL (9.2 mmol) of 
DIPEA in 20 mL of CH3CN was added dropwise 0.6 mL (9.3 mmol) of propargylamine 8a over 
30 min at room temperature. The mixture was stirred at room temperature for 2 h. The solid was 
filtered, washed with water and dried under nitrogen overnight to give 1.4 g (85%) of 9a as a 
white solid (Rf = 0.43, CH2Cl2/MeOH = 9:1). 1H NMR (DMSO-d6): δ 8.11−7.94 (m, 1H), 
9a: R =
9b: R =
9c: R = N3
N
N
N
Cl
H2N Cl
N
N
N
HN
H2N Cl
R
7 9a−c
R NH2
CH3CN, DIPEA, 25 °C, 2 h
84−98%
8a−c
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7.44−7.23 (m, 2H), 4.01−3.98 (m, 2H), 3.07 (t, J = 2.5, 1H). 13C NMR (DMSO-d6): δ 168.3, 
166.6, 165.4, 80.7, 72.2, 29.3. LR-ESI-MS (m/z) calculated for [M + H]+: 184.0; found 184.0. 
Compound 9b: Using the similar procedure as described above, 600 mg (3.6 mmol) of 7, 
0.95 mL (5.5 mmol) of Et3N, and 0.35 mL (4.3 mmol) of 1-amino-3-butyne 8b afforded 660 mg 
(98%) of 9b as a white solid. 1H NMR (DMSO-d6): δ 7.84−7.66 (m, 1H), 7.35−7.14 (m, 2H), 
3.36−3.28 (m, 2H), 2.84−2.82 (m, 1H), 2.39−2.33 (m, 2H). 
Compound 9c: Using the similar procedure as described above, 8.4 g (50.9 mmol) of 7, 
7.5 mL (53.8 mmol) of Et3N, and 6.0 g (59.9 mmol) of 3-azido-propylamine 8c afforded 9.8 g 
(84%) of 9c as a white solid. 1H NMR (DMSO-d6): δ 7.83−7.65 (m, 1H), 7.33−7.10 (m, 2H), 
3.40−3.36 (m, 2H), 3.28−3.23 (m, 2H), 1.75−1.68 (m, 2H).  
Note: compound 7, propargylamine 8a, 3-azido-propylamine 8b, 3-azido-propylamine 8c 
are available from Sigma-Aldrich or can be easily prepared using reported procedures. 
          
Compound 11a: To a mixture of 22 mL (218.9 mmol) of 1,4-diaminobutane 10 in 50 mL 
of MeOH was added slowly 13.0 g (71.1 mmol) of 9a over 30 min at 90 °C. The mixture was 
stirred at 90 °C for 1 h. The solvent and the excess amount of 1,4-diaminobutane were removed 
by distillation. The crude was purified by silica gel column chromatography with a gradient 
mixture of CH2Cl2/MeOH from 9/1 to 4/1 (v/v). Fractions containing product were combined 
and concentrated using a rotary evaporator to give 11.9 g (71%) of 11a as a white solid. 1H NMR 
N
N
N
HN
H2N Cl
R
H2N
NH2
MeOH, 90 °C, 2 h
57−71%
N
N
N
HN
H2N NH
R
NH2
10
9a−c 11a−c
11a: R =
11b: R =
11c: R = N3
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(DMSO-d6): δ 6.83−6.52 (m, 2H), 6.26−5.98 (m, 2H), 4.68 (br s, 2H), 3.97−3.95 (m, 2H), 
3.21−3.15 (m, 2H), 3.00 (t, J = 2.4, 1H), 2.62 (t, J = 6.9, 2H), 1.47−1.39 (m, 4H). 13C NMR: δ 
166.97, 166.73, 165.97, 165.77, 165.57, 82.72, 72.16, 41.31, 30.41, 29.22, 26.89. LR-ESI-MS 
(m/z) calculated for [M + H]+: 236.2; found 236.1.  
Compound 11b: Using the similar procedure as described above, 0.7 g (3.5 mmol) of 9b 
and 1.5 mL (14.9 mmol) of 1,4-diaminobutane 10 afforded 0.5 g (57%) of 11b as a white solid. 
1H NMR (DMSO-d6): δ 6.59−6.45 (m, 2H), 6.22−5.75 (m, 2H), 4.12 (br s, 2H), 3.34−3.29 (m, 
4H), 2.81 (t, J = 2.7, 1H), 2.66 (t, J = 6.8, 2H), 2.33 (br s, 2H), 1.45 (br s, 4H). 
Compound 11c: Using the similar procedure as described above, 9.3 g (40.7 mmol) of 9c 
and 13 mL (129.3 mmol) of 1,4-diaminobutane 10 afforded 7.5 g (66%) of 11c as a white solid. 
1H NMR (DMSO-d6): δ 8.07 (br s, 2H), 6.67−6.46 (m, 2H), 6.17−5.89 (m, 2H), 3.36 (t, J = 6.8, 
2H), 3.23−3.15 (m, 4H), 2.74 (t, J = 7.5, 2H), 1.72−1.69 (m, 2H), 1.59−1.46 (m, 4H). LR-ESI-
MS (m/z) calculated for [M + H]+: 281.2; found 281.1. 
 
Compound 6a: To a white suspension of 1.5 g (5.1 mmol) of diethyl terephthalimidate 
hydrochloride 12 in 30 mL of anhydrous EtOH was added 3.3 mL (23.7 mmol) of anhydrous 
Et3N. To the resulting clear solution was added 13 mL (13.0 mmol) of ethanolic solution of 11a 
1 M. The reaction mixture was stirred at room temperature for 24 h. The solvent was removed 
using a rotary evaporator. The white solid was purified by silica gel column chromatography 
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with a gradient mixture of CH2Cl2/MeOH from 9/1 to 1/9 (v/v). After using 1 L of 
CH2Cl2/MeOH (1:9, v/v), the eluent was acidified with a gradient of 0.1–0.2 mL of dioxane 
solution of HCl 4 M per liter of eluent. The product-containing fractions were combined, filtered, 
and concentrated using a rotary evaporator to give 1.1 g (29%) of 6a as a white tetra-HCl salt. 1H 
NMR (DMSO-d6): δ 10.29 (s, 2H), 9.85 (s, 2H), 9.50−9.47 (m, 2H), 8.70−8.65 (m, 4H), 
8.28−7.99 (m, 8H), 4.10−4.07 (m, 4H), 3.51−3.49 (m, 4H), 3.40−3.33 (m, 4H), 3.24−3.21 (m, 
4H), 1.71−1.62 (m, 8H). HR-ESI-MS (m/z) calculated for [M + H]+: 599.3544; found 599.3536. 
HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 5.1 min (98%). 
Compound 6b: Using the similar procedure as described above, 181 mg (0.61 mmol) of 
12, 0.25 mL (1.8 mmol) of anhydrous Et3N, and 7 mL (1.4 mmol) of ethanolic solution of 11b 
0.2 M afforded 250 mg (52%) of 6b as a white tetra-HCl salt. 1H NMR (DMSO-d6): δ 10.22 (s, 
2H), 9.78 (s, 2H), 9.40 (s, 2H), 8.21−7.73 (m, 14H), 3.48 (q, J = 6.6, 4H), 3.40−3.40 (m, 16H), 
1.71−1.59 (m, 8H). HR-ESI-MS (m/z) calculated for [M + H]+: 627.3857; found 627.3840. 
HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 6.1 min (100%). 
Compound 6c: Using the similar procedure as described above, 261 mg (0.9 mmol) of 12, 
0.35 mL (2.5 mmol) of anhydrous Et3N, and 545 mg (1.9 mmol) of 11c afforded 484 mg (65%) 
of 6c as a white tetra-HCl salt. 1H NMR (DMSO-d6): δ 10.32−10.27 (m, 2H), 9.83 (s, 2H), 
9.49−9.45 (m, 2H), 8.54−8.38 (m, 4H), 8.07−7.92 (m, 8H), 3.51−3.47 (m, 4H), 3.43−3.32 (m, 
12H), 1.80−1.62 (m, 12H). HR-ESI-MS (m/z) calculated for [M + H]+: 689.4198; found 
689.4182. HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 8.7 min 
(100%).  
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Compound 14: To a 50 mL round-bottomed flask containing 690 mg (4.2 mmol) of 
compound 7 was added 10 mL of CH3CN and 0.7 mL (5.0 mmol) of Et3N. The suspension was 
stirred at room temperature for 5 min. To the reaction flask was added 1.7 g (4.9 mmol) of 13 at 
once, giving a clear solution. The reaction was stirred at room temperature for 2 h. Acetonitrile 
was removed using a rotary evaporator. The solid was dissolved in 30 mL of MeOH. To the 
resulting solution was added 2.0 mL (19.9 mmol) of 1,4-diaminobutane 10 at once. The reaction 
was heated to 90 °C, and stirred for 1 h. Methanol and the excess amount of diaminobutane were 
removed by a rotary evaporator. The crude was purified by silica gel column chromatography 
with a mixture of CH2Cl2/MeOH/NH4OH (90/9/1, v/v/v). Fractions containing product were 
combined and concentrated to give 1.3 g (59%) of compound 14 as a white solid. 1H NMR 
(DMSO-d6): δ 6.75 (br s, 2H), 6.53–5.81 (m, 4H), 3.19–3.14 (m, 4H), 2.97 (br s, 4H), 2.56–2.53 
(t, J = 6.9, 2H), 2.46–2.44 (t, J = 6.5, 6H,), 1.49–1.30 (m, 4H), 1.37 (br s, 18H). LR-ESI-MS 
(m/z) calculated for [M + H]+: 527.4; found 527.2. 
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Compound 15: To a 100 mL oven-dried round-bottomed flask was added 250 mg (0.9 
mmol) of 12. The white solid was dissolved in 15 mL of anhydrous EtOH. To the resulting 
suspension was added 0.3 mL (2.2 mmol) of anhydrous Et3N followed by 1.0 g (1.9 mmol) of 14 
at once. The resulting suspension was stirred at room temperature for 1 d. The solvent was 
removed using a rotary evaporator. The crude was dissolved in 20 mL of ethanolic solution of 
HCl 2 M. The reaction was stirred at room temperature overnight. Ethanol was removed using a 
rotary evaporator. The crude was purified by a Sephadex CM-25 column chromatography using 
aqueous solution of NH4HCO3 from 0.1 M to 1.0 M. Fractions containing products were 
combined and concentrated at 60 °C using a rotary evaporator. The solid was dissolved in 80 mL 
of aqueous solution of HCl 0.1 M. The resulting solution was concentrated using a rotary 
evaporator to give 390 mg (40%) of compound 15 as a white HCl salt. 1H NMR (DMSO-d6): δ 
10.10 (s, 2H), 9.70 (s, 2H), 9.26 (s, 2H), 8.42–7.79 (m, 26H), 3.45–3.32 (m, 12H), 2.90 (s, 8H), 
2.70–2.61 (m, 12H), 1.69–1.60 (m, 8H). LR-ESI-MS (m/z) calculated for [M + H]+: 781.6; found 
781.6. 
2.5.2 Isothermal Titration Calorimetry 
RNA sequences were purchased from Integrated DNA Technology (Coralville, IA). The 
RNA solid was dissolved in the RNA storage buffer containing 1 mM sodium citrate pH 6.4 
(Ambion® #AM7001).  
The ligand stock solutions (10 mM in water), MOPS buffer (100 mM; pH 7.0 ± 0.2), and 
NaCl (5000 mM) were prepared.  The ligand solution (1 mL) contained 0.5 mM of ligand, 20 
mM of MOPS buffer, and 150 mM of NaCl. The RNA solution (2 mL) contained 0.02 mM of 
RNA, 20 mM of MOPS buffer, and 150 mM of NaCl. The resulting RNA solution was heated in 
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a water bath at 90 °C for 5 min, then allowed to cool slowly to room temperature for 2 h.  
ITC measurements were performed at 25 °C on a MicroCal VP-ITC calorimeter 
(Northampton, MA) in Microanalysis Laboratory, University of Illinois at Urbana-Champaign. A 
typical experiment consisted of 30 injections of a ligand solution (500 µM) from a 298 µL 
syringe into an RNA solution (10 µM, 1.42 mL) stirred at 300 rpm (1 µL for the first injection 
and 10 µL for the remaining). The initial delay prior to the first injection was 60 s. The duration 
of each injection was 20.5 s and the delay between injections was 400 s. Data was analyzed 
using Origin 5.0 software (MicroCal). Binding parameters such as the dissociation constant (KD), 
enthalpy change (ΔH), and entropy change (ΔS) were determined by fitting the experimental 
binding isotherms with an appropriate model.  
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CHAPTER 3 
DEVELOPMENT OF THE BISAMIDINIUM DIMERIC LIGANDS2 
3.1 Introduction 
As described in Chapter 1, the causative agent of DM1 is the rCUG repeats whose length 
varies from 50 to thousands repeats. Although ligands 1–4 exhibit promising inhibitory activities, 
they likely span only 1-3 adjacent U-U sites and certainly no more than three U-U mismatches. 
We anticipate that a multivalent or modularly assembled ligand containing two or more RNA-
binding molecules would exhibit improved inhibition of the MBNL1-rCUGexp complex. In 2013, 
Zimmerman and coworkers evaluated a library of dimeric ligands, which are comprised of two 
melamine-acridine units connected by different oligoether and oligoamino linkers.44 Compared 
with the monomeric ligand, the most potent compound 3, exhibited a 206-fold greater binding 
affinity to r(CUG)6 and a 266-fold greater inhibition of the MBNL1-r(CUG)12 complex. 
Advantageously, compound 3 is also water soluble, able to enter the nuclei and fully disrupt 
nuclear foci at 50 µM.  
In this chapter, the synthesis and biological activities of the bisamidinium-based bivalent 
ligands are described. Dimer 20a was found to be a potent MBNL1-rCUGexp complex inhibitor 
with a low nanomolar KI. However, its efficacy in DM1 model cells was not what might be 
expected for such a strong inhibitor, which may be attributed to its low cellular permeability 
resulting from the high molecular weight of the dimer (Mr = 1166.4 Da). In addition, the 																																																								
2 Some of the material in this chapter was adapted from the following publication: 
Luu, L. M.; Nguyen, L.; Peng, S.; Lee, J.; Lee, H. Y.; Wong, C.-H.; Hergenrother, P. J.; Chan, H. Y. E.; 
Zimmerman, S. C. ChemMedChem 2016, 11, 1428–1435. 
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compound has a significantly lower maximum tolerated dose (MTD) in mice than that of the 
monomeric ligand. These important observations suggest a need to access the potency of the 
dimer while still retaining some of the favorable attributes of the monomer. 
3.2 Design and Synthesis of the Dimeric Ligands 
It was previously shown that compounds 6a−c containing alkyne and azide groups 
exhibit comparable binding affinities toward rCUG repeats with compound 4. Thus, the linker 
that connects the two modules of the bisamidinium dimer should be placed on the 
triaminotriazine unit. Initial attempt to prepare a bisamidinium dimer was to link ligands 6a and 
6c using the copper-catalyzed click reaction (Scheme 3). The copper(I) was generated in situ 
from the reduction of copper(II) sulfate by sodium ascorbate.50 Tris[(1-benzyl-1H-1,2,3-triazol-
4-yl)methyl]amine (TBTA) was employed to prevent CuI from oxidizing to CuII.51 Interestingly, 
the alkyne-azide cycloaddition of 6a and 6b mainly afforded cyclic dimer 16, which was 
characterized by the loss of the acetylene proton and carbon in 1H and 13C NMR. The low yield 
was attributed to the loss of compound during the purification process.  
 
Scheme 3. Synthesis of cyclic dimer 16. 
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 To prepare linear bisamidinium dimers, compounds containing one clickable moiety were 
synthesized (Scheme 4). The preparation of unsymmetrical ligands was more challenging, 
because the remaining imidate ester group in compound 18 is susceptible to hydrolysis and 
alcoholysis. Therefore, compound 17 was added slowly to the excess amount of imidate ester 12 
to produce 18 with a small amount of 4 as indicated on TLC and ESI-MS. Reactions of 18 with 
the melamine 11a−c afforded ligands 19a−c in moderate yields.  
Dimers 20a−b were prepared from the click reaction of 19a−b and 19c (Scheme 5). 
Because the starting materials and the byproducts are composed of varying number of positive 
charges, dimers 20a−b were purified by an ion exchange column chromatography (Sephadex 
Scheme 5. Synthesis of dimers 20a−b. 
 
Scheme 4. Synthesis of ligands 20a−c.  
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CM-25). Compounds 20a−b in HCl salt form were obtained with a purity of greater than 95% 
pure as indicated by 1H NMR spectroscopy, and analytical HPLC. 
3.3 Inhibition of the MBNL1-r(CUG)16 Complex by Dimeric Ligands  
Inhibition of the MBNL1-r(CUG)16 complex was evaluated by electrophoretic mobility 
shift assay (EMSA). Because of the high sensitivity of the radioisotope-labeled RNA, EMSA 
requires small amounts of both RNA and protein, making it widely used to study the binding of 
protein and RNA as well as the inhibition of protein-RNA interactions.52 Because monomer 4 
was designed to span three U-U mismatches, the r(CUG)16 containing a maximum of eight U-U 
mismatches would provide at least one binding site for dimers 20a−b.45 In this study, MBNL1N, 
a truncated MBNL1 containing four zinc finger motifs of MBNL1 and a hexahistidine tag (C-
terminus) was employed. The MBNL1N construct and the full-length MBNL1 have similar 
affinities to rCUGexp.53 The MBNL1-r(CUG)16 complex and the free RNA were separated on a 
6% polyacrylamide gel at 4 °C, pH 8.2−8.3, and visualized by the autoradiography of the 32P-
labeled RNA. The ability of ligands to displace MBNL1 from its complex with rCUG repeats 
was judged by the ratio of bound RNA to the total amount of RNA. 
Firstly, a head-to-head comparison between monomers 4, 6a, 6c, and dimers 16, 20a, 20b 
was conducted (Figure 9). The concentrations of MBNL1 and r(CUG)16 were selected to have ca. 
46% of r(CUG)16 complexed to MBNL1. Under the treatment of ligands, more free RNA was 
observed. As can be seen in Figure 9, ligands 4 and 6a exhibited similar inhibition potency at 10 
and 100 µM, whereas a small improvement was observed for ligand 6c. It is noteworthy that all 
three monomers were inactive at 10 µM, whereas most of the MBNL1-r(CUG)16 complex was 
disrupted by the dimers. When the concentration of the dimers was reduced to 1 µM, ca. 25−40% 
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of the MBNL1-r(CUG)16 complex remained. This single experiment suggested that linear dimers 
exhibited highest inhibition potency.  
The in vitro inhibition constants (KI) of monomer 4 and dimers 20a−b were quantitatively 
determined by EMSA (Figure 10a). In this study, an apparent binding constant (KD) of MBNL1-
r(CUG)16 was 5.1 ± 1.6 nM, which is comparable to reported KD values by EMSA and other 
techniques.43,45 To determine the inhibition constant, the MBNL1-r(CUG)16 complex, in which 
ca. 50% of the total RNA was free, was incubated with ligands at different concentrations. The 
concentration of dimers were not raised above 5 µM because of the their aggregation at higher 
concentrations. As the ligand concentration increased, more RNA was released from the complex 
with MBNL1. The IC50 value was determined by fitting the plot of bound RNA fractions versus 
ligand concentrations with an appropriate equation (Figure 10b). 
Compound 4, dimers 20a−b exhibited IC50 values of 188 ± 32 µM, 290 ± 20 nM, and 430 
 
Figure 9. Head-to-head comparison of inhibition of the MBNL1-r(CUG)16 complex by monomers 4, 
6a, 6c and dimers 16, 20a, 20b using EMSA. (This experiment was conducted by Dr. Lien Nguyen) 
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± 30 nM, and calculated KI values of 16 ± 6 µM, 25 ± 8 nM, and 37 ± 12 µM, respectively. The 
significantly improved inhibitory potency (ca. 1000-fold) is likely attributed to bivalent binding 
to r(CUG)16 of dimers. A binding study by ITC showed that the binding of 20a to r(CUG)16 
produced significantly more heat than does the monomers (Figure 11). Although, the binding 
isotherm indicates a positively cooperative system, additional experiments are needed to fully 
elucidate the binding mode and to quantitatively determine the affinity of the dimeric ligands. 
Beyond their greater RNA affinity, dimeric ligands cover a greater surface area of the rCUGexp 
target than does monomer 4. 
 
 
 
Figure 10. Determination of inhibition constants, KI, by EMSA. (a) Representative gels show the 
dissociation of r(CUG)16 from the complex with MBNL1 at different concentrations of 4 and 20a−b. (b) 
The IC50 value was obtained by plotting the normalized fraction RNA bound versus the ligand 
concentration. Error bars represent the standard deviation from three independent experiments.  
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3.4 Biological Activities of the Dimers in DM1 Model Cells 
3.4.1 Foci Disruption 
Because of the slightly lower KI value and the lower cost of starting materials, dimer 20a 
was selected for the cellular and animal assays. Before the efficacy of 20a was evaluated in cells, 
its cytotoxicity to HeLa cells was studied in a sulforhodamine B (SRB) colorimetric assay. It was 
found that the dimer exhibited negligible cellular toxicity up to 100 µM after a 3-day treatment 
(Figure 12). At 100 µM, only ~10% HeLa cell death was observed, demonstrating the advantage 
of the bisamidinium-based dimer over the acridine-containing dimers.44  
Disruption of the MBNL1-rCUGexp foci in DM1 model cells was conducted by Dr. Lien 
			 	
Figure 11. ITC binding isotherm obtained from the titration of 4 (left) and 20a (right) to r(CUG)16 at 25 
°C, pH 7.0 (MOPS 20 mM, NaCl 150 mM). 
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Nguyen using a confocal microscopy experiment with immunofluorescence staining and 
fluorescent in situ hybridization  (Figure 13a).49 DM1 model cells were generated by transfecting 
HeLa cells with GFP-DT960 plasmid containing (CTG)960 in exon 15 of a truncated DMPK 
gene, while cells with GFP-DT0 served as normal cells. The endogenous MBNL1 protein and 
rCUG transcript were detected by Alexa Fluor 647 dye-labeled antibody (green spots in column 
1), and (CAG)10 conjugated with a Cy3 dye (red spots in column 2). The blue areas are the 
nucleus stained by Hoechst 33342 (column 3).  
MBNL1 was distributed throughout the nucleus in normal cells, whereas in DM1 model 
cells, it was concentrated in nuclear foci with rCUG repeats. A head-to-head comparison 
between 4 and 20a was performed to evaluate the improvement of the dimeric ligand. Under the 
treatment of 20a at 1 µM for 48 h, the number of foci decreased to ca. 72%. A similar effect was 
achieved with 4 at 100 µM over the same period of time (Figure 13b). Although it is encouraging 
that dimeric ligand 20a is as active at 1 µM as monomeric ligand 4 is at 100 µM, it is surprising 
that full foci dispersion is not observed at higher concentrations. Incubation of 20a at 10 µM 
decreased the foci area to ~36%, but a similar level was also observed for treatment at 100 µM. 
The lack of full dose dependence and its inability to fully disrupt nuclear foci suggest a cellular 
	
Figure 12. Cytotoxicity of 20a to HeLa cells. (This experiment was conducted by Dr. Lien Nguyen) 
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Figure 13. Foci disruption in DM1 model cells by ligands 4 and 20a. (a) Representative confocal 
microscope images. (b) Percent of foci area per cell after treatment of ligands for 48 h. Error bars 
represent standard errors of mean from at least four independent experiments, two-tailed t-test * 
P<0.005. (This experiment was conducted by Dr. Lien Nguyen) 
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penetration issue for 20a.  
The foci dispersion was also carried out by Dr. Lien Nguyen using exogenous GFP-
MBNL1 with similar results (Figure 14). For the normal cells, HeLa cells were transfected with a 
plasmid containing GFP-MBNL1. DM1 model cells were generated by transfecting HeLa cells 
 
Figure 14. Representative confocal microscopy images. r(CUG)960 was visualized by Cy3-(CAG)10, and 
appeared as red dots in the second column. The nuclei was stained by TO-PRO-3, and appeared as blue 
in the third column. Images in columns 1−3 were merged in column 4. (This experiment was conducted 
by Dr. Lien Nguyen) 
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with 2 plasmids, GFP-MBNL1 and a DMPK plasmid containing (CTG)960. The MBNL1 were 
labeled in green by GFP, whereas r(CUG)960 was visualized by the FISH probe Cy3-(CAG)10 
and was represented by the red color. In normal cells, MBNL1 was distributed in the entire 
nucleus. Because of the absence of rCUG repeats, no red signal of Cy3 was observed. In DM1 
model cells, MBNL1 protein was concentrated in bright green spots, which were co-localized 
with the red spots of rCUG repeats in the nucleus. It was found that the number of nuclear foci 
was decreased to 70%, 30%, and 12% after treatment with 20a for 48 h at 1, 10, 100 µM, 
respectively. On the other hand, treatment of ligand 4 at 100 µM for 48 h incubation resulted in a 
reduction of foci to ca. 60%.  
3.4.2 Splicing Correction 
Previous studies provided evidence for the inhibition of MBNL1-rCUGexp by 20a both in 
vitro and in DM1 model cells. Therefore, its capacity to correct the splicing defects in DM1 
Figure 15. a) Schematic representation of IR alternative splicing. b) Correction of IR splicing by 20a 
and 4 determined by conventional RT-PCR. Error bars represent standard error of the mean from at least 
three independent experiments, two-tailed t-test * P < 0.05, *** P < 0.001. (This experiment was 
conducted by JuYeon Lee and Dr. Lien Nguyen) 
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model cells was addressed in this part using an IR minigene (Figure 15). During the alternative 
splicing of IR, two products are generated: isoforms IR-A and IR-B with the exclusion and 
inclusion of exon 11, respectively (Figure 15a). In normal skeletal muscle, IR-B is the dominant 
isoform, whereas IR-A is more abundant in DM1 skeletal muscle. 19 We found that normal HeLa 
cells and the DM1 model cells contained ~49 and 26% isoform B, respectively (Figure 15b). The 
treatment of 20a in DM1 model cells showed a dose-dependent reversal of IR splicing with a full 
recovery at 100 µM. Although 20a exhibited a low nanomolar inhibition constant for the 
MBNL1-rCUGexp complex in vitro, a full recovery of IR splicing defect was not achieved at a 
lower concentration, demonstrating the limited cellular uptake of 20a. 
3.5 Efficacy of Dimers in a DM1 Drosophila Model 
Determining drug efficacy in a living organism is a critical step in drug development. The 
Drosophila line with tissue-specific expression of 480 interrupted CTG repeats, i(CTG)480, 
shows many key characteristics of DM1, such as nuclear accumulation of rCUGexp and MBNL 
proteins, CUG-induced eye phenotypes, muscle degeneration, and abnormal alternative splicing 
of muscle genes.54,55 In contrast, the fly line expressing 60 uninterrupted CTG repeats, (CTG)60, 
does not exhibit severe pathologies. Several small molecules were reported to improve the CUG-
induced phenotypes in the DM1 Drosophila model,56 including our previous studies of 4.45 The 
comparative effectiveness of 4 and 20a in suppressing the external eye degeneration phenotype 
and improving larva mobility was examined in the DM1 Drosophila model.  
Similar to the reported DM1 Drosophila model,54 our transgenic fly model with the gmr-
GAL4 driven expression of i(CUG)480 repeats (gmr-GAL4>UAS-i(CTG)480) showed external eye 
morphological phenotypes, including disorganized ommatidia and mechanosensory bristles, 
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resulting in a glossy eye (Figure 16). The microscopic images showed that treatment with 20a at 
50 µM led to partial reversal of the degenerative phenotype, whereas the same effect was 
achieved by monomer 4 at 400 µM (Figure 16). On the other hand, treatments of (CTG)60 
Drosophila flies treated with either 4 or 20a at 400 µM did not change the eye structure. 
In addition, 4 and 20a significantly improved the locomotor ability of i(CTG)480 DM1 
Drosophila larvae in a larval crawling assay.57 In this assay, an individual larva generated from 
transgenic flies was placed on a Petri dish over graph paper, and allowed to crawl (Figure 17a). 
	
Figure 16. Improvement in adult external eye degeneration phenotype in DM1 Drosophila fly model. 
Each experiment was conducted in triplicate. (This experiment was conducted by Shaohong Peng and 
Prof. H. Y. Edwin Chan, The Chinese University of Hong Kong)  
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The (CTG)60 control larvae were able to crawl ~13 lines per minute, whereas the i(CTG)480 DM1 
larvae could cross only nine lines (Figure 17b), demonstrating their locomotor defect. When the 
control larvae were raised with an aqueous solution of fly food containing either 4 or 20a at 400 
µM, the mobility was not affected (Figure 17c), suggesting low toxicity of the bisamidinium 
 
Figure 17. Effect of 4 and 20a in a larval crawling assay. a) Illustration of the larvae crawling on the 
Petri dish. Images were adapted from the video in Ref 57. b) Dose-dependent effect of ligands on the 
DM1 larvae (24B-GAL4 > UAS-i(CTG)480). (c) Effect of ligands on the control Drosophila larvae (24B-
GAL4 > UAS-(CTG)60). Each experiment was conducted in triplicate, 10 individual larvae for each trial. 
Error bars represent standard deviation, two tailed t-test * P < 0.05, ** P < 0.01, *** P < 0.001. (This 
experiment was conducted by Shaohong Peng and Prof. H. Y. Edwin Chan, The Chinese University of 
Hong Kong) 
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ligands. Treatment of the i(CTG)480 DM1 larvae with 4 at 100, 200, 400 µM rescued ~14, 54, and 
84% of the crawling defect, respectively, demonstrating dose-dependent response (Figure 17b).  
Compared with 4, dimer 20a showed greater efficacy with a nearly full recovery at 100 µM. 
Even at concentrations as low as 20 µM, 20a induced a 37% improvement in the DM1 larva's 
mobility. To our knowledge, this is the first example of a small molecule showing a substantial 
improvement in locomotor behavior or muscle performance defect of the DM1 Drosophila 
larvae. 
However, the maximum tolerated dose (MTD) of 20a in mice was a relatively low 3 
mg/kg as determined by daily intraperitoneal injections. 
3.6 Conclusions and Outlook 
In summary, dimeric ligand 20a, prepared by copper-catalyzed click reaction, exhibits an 
excellent in vitro inhibition of the MBNL1-rCUGexp complex, but its desired efficacy in DM1 
model cells was not observed. The potential issues with cell permeability may be attributed to its 
high molecular weight and increased number of hydrogen bond donors and acceptors.58 
However, the clear dose-dependent phenotypic improvement in the Drosophila models supports 
the notion that the bis-amidinium dimer may be useful if delivery and toxicity issues can be 
addressed. Two clear solutions involve the use of a delivery vehicle or in vivo self-assembly of 
the clickable monomers. The latter approach is particularly appealing, because monomer 4 is 
nontoxic to mice at 50−100 mg/kg.45 Efforts along these lines will be reported in due course.  
The use of copper catalyst to assemble the dimer and trimer is an alternative solution. 
Recently, Zimmerman and coworkers developed a copper nanoparticle that was found to 
catalyze the alkyne-azide click reaction at a ppm concentration, making this catalyst relatively 
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nontoxic to cells at the working concentration.59 The evaluation of this catalyst in the 
cycloaddition of diazide 6c and alkyne 19a, which potentially produces dimer 21 and trimer 22 
(Figure 18), is currently ongoing. 
3.7 Materials and Methods 
3.7.1 Synthesis 
 
Compound 16. To a solution containing 33 mg (0.042 mmol) of 6a and 49 mg (0.043 
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Figure 18. Structures of dimer 21 and trimer 22.  
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mmol) of 6c in 10 mL of MeOH was added 127 µL of DMSO solution of TBTA 0.1 M, 849 µL 
of aqueous solution of sodium ascorbate 0.1 M, and 212 µL of aqueous solution of Cu2SO4.5H2O 
0.1 M. The mixture was stirred at room temperature for 24 h. Solvents were removed using a 
rotary evaporator. The resulting solid was suspended in 10 mL water. The suspension was 
filtered using a syringe filter (28mm diameter, 0.45 µm pore SFCA membrane, Corning® 
#431220) to obtain a clear solution. Concentrated aqueous solution of HCl was added to adjust to 
pH of the solution to 5−6. The resulting solution was loaded onto the Sephadex CM-25 column, 
and purified using aqueous solution of NH4HCO3 from 0.5 to 0.9 M. Fractions containing the 
product was collected, concentrated using a rotary evaporator at 60 °C. The solid was dissolved 
in 5 mL of aqueous solution of HCl 1 M. The resulting solution was frozen in an dry-ice bath, 
and dried in a lyophilizer for 2 days, gave 20 mg (29%) of 16 as a white solid. 1H NMR (DMSO-
d6): δ 10.33 (s, 4H), 9.84 (s, 4H), 9.49 (s, 4H), 8.81−7.93 (m, 24H), 4.55−4.50 (m, 4H), 
4.41−4.38 (m, 4H), 3.51−3.49 (m, 8H), 3.34−3.27 (m, 12H), 2.05 (q, J = 6.5, 4H), 1.68−1.60 (m, 
16H). 13C NMR (DMSO-d6): δ 161.50, 155.84, 155.74, 132.75, 128.70, 128.66, 123.25, 47.16, 
42.44, 37.66, 35.98, 29.52, 25.91, 24.65. 
 
Compound 18. To a white suspension of 5.0 g (17.1 mmol) of 12 in 30 mL of anhydrous 
EtOH was added 7.5 mL (53.8 mmol) of anhydrous Et3N, resulting in a colorless solution. A 
suspension of 1.1 g (5.7 mmol) of 1741 in 10 mL of anhydrous EtOH was added slowly to the 
reaction mixture. The reaction was stirred at room temperature for 24 h. The white solid was 
N
N
N
NH2
H2N NH
NH2
HN
EtO
NH
OEt
• 2 HCl
12
17
EtOH, Et3N, 25 °C, 24 h
97%
N
N
N
NH2
H2N NH
NH
NH
OEt
HN
18
	 40 
filtered, washed extensively with CH2Cl2, dried under nitrogen overnight to give 2.1 g (97 %) of 
compound 18 as a white solid. Compound 18 was used for the next step without further 
purification because the imidate ester is water sensitive. LR-ESI-MS (m/z) calculated for [M + 
H]+: 372.2, found: 372.2. 
 
Compound 19a. A suspension of 4.0 g (10.8 mmol) of 18 and 2.8 g (11.9 mmol) of 11a 
in 50 mL of anhydrous EtOH was stirred at room temperature overnight. The solvent was 
removed using a rotary evaporator. The resulting white solid was purified by silica gel column 
chromatography with a gradient mixture of CH2Cl2/ MeOH from 9/1 to 1/9 (v/v). After using 1 L 
of CH2Cl2/MeOH (1:9, v/v), the eluent was acidified with a gradient of 0.10−0.2 mL of dioxane 
solution of HCl 4 M per liter of eluent. The product-containing fractions were combined, filtered, 
and concentrated using a rotary evaporator to give 5.4 g (71%) of 19a as a white tetra-HCl salt. 
1H NMR: δ 10.11 (s, 2H), 9.73 (s, 2H), 9.30 (s, 2H), 7.95 (s, 4H), 6.87−6.54 (m, 3H), 6.10−5.95 
(m, 6H), 3.97 (s, 2H), 3.45 (t, J = 7.1, 4H), 3.25−3.21 (m, 4H), 3.01 (t, J = 2.4, 1H), 1.70−1.53 
(m, 8H); LR-ESI-MS (m/z) calculated for [M + H]+: 561.3, found: 561.4. 
Compound 19b. Using the procedure described above, 0.3 g (0.8 mmol) of 18 and 5 mL 
(1.0 mmol) of 0.2 M ethanolic solution of 11b afforded 0.3 g (52%) of 19b as a white tetra-HCl 
salt. LR-ESI-MS (m/z) calculated for [M + H]+: 575.4, found: 575.5. 
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Compound 19c. Using the procedure described above, 3.5 g (9.4 mmol) of 18 and 2.9 g 
(10.4 mmol) of 11c afforded 4.3 g (61%) of 19c as a white tetra-HCl salt. 1H NMR: δ 10.13 (s, 
2H), 9.74 (s, 2H), 9.32 (s, 2H), 7.95 (s, 4H), 6.63−6.48 (m, 3H), 6.11−5.95 (m, 6H), 3.45 (t, J = 
7.2, 4H), 3.38−3.54 (m, 4H), 3.24−3.21 (m, 4H), 1.74−1.53 (m, 10H); LR-ESI-MS (m/z) 
calculated for [M + H]+: 606.4, found: 606.2. 
 
Compound 20a. To a solution containing 34 mg (0.049 mmol) of 19a and 37 mg (0.049 
mmol) of 19c in 11 mL of MeOH was added 148 µL (0.015 mmol) of DMSO solution of TBTA 
0.1 M, 246 µL (0.025 mmol) of aqueous solution of CuSO4.5H2O 0.1 M. To the resulting 
solution was added 985 µL (0.099 mmol) of aqueous solution of sodium ascorbate 0.1 M. The 
mixture was stirred at room temperature for 24 h. Solvents were removed using a rotary 
evaporator. The resulting solid was suspended in 10 mL water. The suspension was filtered using 
a micro-filter to obtain a clear solution. Concentrated aqueous solution of HCl was added to 
adjust the solution to pH 5−6. The resulting solution was loaded onto the Sephadex CM-25 
column, and purified using an aqueous solution of NH4HCO3 from 0.1 to 0.9 M. Fractions 
containing the product was collected, concentrated using a rotary evaporator at 60 °C. The solid 
was dissolved in 5 mL of aqueous solution of HCl 1 M. The resulting solution was frozen in an 
dry-ice bath, and dried in a lyophilizer for two days, giving 27 mg (38%) of 20a as a white solid. 
1H NMR: δ 10.30 (s, 4H), 9.83 (s, 4H), 9.50−9.46 (m, 4H), 8.58−7.86 (m, 26H), 4.57−4.52 (m, 
2H), 4.42−4.39 (m, 2H), 3.51−3.47 (m, 8H), 3.38−3.27 (m, 10H), 2.08−2.06 (m, 2H), 1.72−1.59 
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(m, 16H); 13C NMR: δ 161.61, 132.84, 128.70, 128.68, 47.08, 42.46, 29.52, 25.98, 24.61; LR-
ESI-MS (m/z) calculated for [M + H]+: 1166.7, found: 584.0 (35%) [M + 2H]2+, 389.7 (60%) [M 
+ 3H]3+, 292.6 (100%) [M + 4H]4+; HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 
mL/min): t = 3.9 min (100%). 
Compound 20b. Using the general procedure described above, 39 mg (0.054 mmol) of 
19b and 40 mg (0.054 mmol) of 19c afforded 26 mg (32%) of 20b as a white solid: 1H NMR: δ 
10.30 (s, 4H), 9.83 (s, 4H), 9.50−9.47 (s, 4H), 8.51−7.87 (m, 26H), 4.39 (t, J = 7.2, 2H), 
3.56−3.47 (m, 10H), 3.36−3.26 (m, 10H), 2.90−2.86 (m, 2H), 2.07−2.04 (m, 2H), 1.71−1.59 (m, 
16H); 13C NMR: δ 161.56, 155.70, 132.79, 128.63, 122.90, 47.01, 42.43, 25.93, 24.56; LR-ESI-
MS (m/z) calculated for [M + H]+: 1180.7, found: 591.1 (15%) [M + 2H]2+, 394.4 (35%) [M + 
3H]3+, 296.1 (45%) [M + 4H]4+, 237.1 (60%) [M + 5H]5+, 197.7 (100%) [M + 6H]6+; HPLC 
(0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 3.8 min (97%). 
3.7.2 Biological Assays 
Protein expression and purification. An expression vector for MBNL1N was obtained 
from Maurice S. Swanson (University of Florida, College of Medicine, Gainesville, FL, USA). 
MBNL1N is comprised of the four zinc finger motifs of MBNL1 and contains a His6 tag. The 
protein was expressed and purified as described previously.45 The molecular weight of MBNL1N 
was determined by MALDI-MS, and the concentration was determined by an amino acid 
analysis. 
Determination of dissociation constant (KD) of the MBNL1-r(CUG)16 complex by 
EMSA. r(CUG)16 was purchased from Integrated DNA Technology (Coralville, IA), dissolved in 
RNA storage buffer containing 1 mM sodium citrate pH 6.4 (Ambion® #AM7001). r(CUG)16 
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RNA was labeled with [γ-32P]-ATP using T4 poly-nucleotide kinase (New England Biolabs). 
Labeled RNA was purified by phenol extraction and ethanol precipitation. Labeled RNA was 
heated at 95 °C for 5 min, then placed on ice for 10 min and diluted in protein binding buffer 
(175 mM NaCl, 5 mM MgCl2, 20 mM Tris-HCl (pH 8), 1.25 mM 2-mercapto-ethanol (BME), 
12.5% glycerol, 2mg/ml bovine serum albumin (BSA), 0.1 mg/ml heparin, 0.05% or 0.1% Triton 
X). For MBNL1-r(CUG)16 binding study, MBNL1 was serially diluted by a factor of 3 in protein 
binding buffer. To each solution was added labeled RNA, so that the final concentration of RNA 
was 0.2 nM. The resulting mixtures were incubated at room temperature for 10 min and loaded 
onto a 6% polyacrylamide gel (80:1) at 4 °C. The gel was run for 2 h at 180 V in Tris-Borate 
0.5X buffer (pH 8.2–8.3). Gels were dried at 80 °C under high vacuum for 2 h, developed 
overnight in phosphor exposure cassette, and visualized on a Molecular Dynamics Storm 
PhosphorImager. The KD (1:1 stoichiometry assumption) was obtained by fitting the normalized 
fraction RNA bound versus the concentration of protein using the equation:  
Fraction RNA bound = Bmax × [MBNL1]totalh/(KDh + MBNL1]totalh) 
 
Figure 19. Dissociation constant of the MBNL1-r(CUG)16 interaction determined by EMSA. The 
concentration of the protein was serially diluted by the factor of 3 from 1.67 µM to 1.05 fM. The 
concentration of r(CUG)16 was 0.2 nM. Error bars represent standard deviation from three independent 
experiments.  
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where Bmax is maximum fraction RNA bound, h is a Hill slope. Protein concentration in 
reaction mixture was larger 10-fold excess over RNA concentration.  
Inhibition of MBNL1-r(CUG)16 complex by small molecules. Labeled RNA was 
heated at 95 °C for 5 min, then placed on ice for 10 min. The MBNL1 and labeled r(CUG)16 
were diluted in protein binding buffer (175 mM NaCl, 5 mM MgCl2, 20 mM Tris-HCl (pH 8), 
1.25 mM 2-mercapto-ethanol (BME), 12.5% glycerol, 2mg/ml bovine serum albumin (BSA), 0.1 
mg/ml heparin, 0.05% or 0.1% Triton X). The complex was incubated at room temperature for 
10 min. For the inhibition assay, compound was serially diluted by a factor of 2 in water. To 
each solution was added the MBNL1-r(CUG)16 complex, so that the final concentrations of RNA 
and protein were 0.2 and 60 nM, respectively. The resulting mixtures were incubated at room 
temperature for 10 min, and loaded onto a 6% polyacrylamide gel (80:1) at 4 °C. The gel was run 
for 1.5 h at 180 V in Tris-Borate 0.5X buffer (pH 8.2−8.3). Gels were dried at 80 °C under high 
vacuum for 2 h, developed overnight in phosphor exposure cassette, and visualized on a 
Molecular Dynamics Storm PhosphorImager. The IC50 value was obtained by fitting the 
normalized fraction RNA bound versus the concentration of compound using the equation in 
Prism:  
y = axb/(IC50b + xb)  
where y is the fraction of RNA bound, x is the concentration of  compound, a = ymax - 
ymin, b is a Hill slope. The average IC50 and standard deviation were obtained from three 
independent experiments. 
The apparent inhibition constant (KI) was determined using the equation:  
KI = IC50 × KD / [protein]total, where [protein]total = 0.06 µM, KD is the dissociation 
constant of the MBNL1-RNA complex and [protein] is at least 7-fold greater than the KD.  
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Binding study using ITC. The ITC experiment was performed as described in Chapter 
2. The concentrations of dimer 20a in the syringe and r(CUG)16 in the cell are 500 µM and 10 
µM, respectively. [MOPS] = 20 mM, [NaCl] = 150 mM. 
Foci dispersion in DM1 models cells using GFP-MBNL1. The foci disruption 
experiments using GFP-MBNL1 were conducted by Dr. Lien Nguyen as described previously.43 
Normal cells were produced by transfecting HeLa cells with a plasmid containing GFP-MBNL1 
and a DMPK plasmid containing no CTG repeats. To generate DM1 model cells, HeLa cells 
were transfected with a GFP-MBNL1 plasmid and a DMPK plasmid containing (CTG)960. The 
DM1 model cells were treated with ligands 4 and 20a for 48 h. The Cy3-(CAG)10 was employed 
to detect rCUG repeats, while the nuclei were stained with Hoechst 33342. The cells were 
visualized using the confocal microscope LSM 700 (Zeiss). GFP tag, Cy3 and Hoechst 33342 
dyes were excited at 488, 564, and 405 nm, respectively. Each treatment was repeated at least 
three times.  
Splicing assays. Splicing assays were carried out essentially by Dr. Lien Nguyen and 
JuYeon Lee as previously described.45 Briefly, cells were seeded in each well in a 6-well plate 
the day before transfection to afford 70−80% of confluence on the following day. The cells were 
co-transfected with 500 ng of IR minigene and either 750 ng of DT960 or 500 ng of DT0 
minigene with Lipofectamine 2000 (Invitrogen, Life Technologies) according to the 
manufacturer’s protocol. After 4h, the media was changed to the complete growth media, and 
cells were treated with the compounds and harvested after 72h. For dose dependence 
experiments, cells were treated with 20a at concentrations of at 10, 1, 0.5, 0.1 µM. And for the 
comparison of 20a and 4, 100 µM of each compound were treated to the cells. To harvest the 
cells, cells were detached using trypsin with 0.05% EDTA (Fisher Mediatech) and collected by 
	 46 
centrifugation at 500 g for 5 min. Out of the collected cells, was RNA immediately isolated using 
Total RNA kit I (Omega Bio-Tek). cDNA was synthesized from 1 µg of isolated RNA with 
iScript cDNA synthesis kit (Bio-Rad). The reverse transcription reaction was purified using 
QIAquick PCR purification kit (Quiagen). Then, 70 ng of cDNA was used for PCR amplification 
of IR isoforms A and B using specific primers. PCR cycle was optimized to 31–35 for each 
assay. The forward primer was 5’- GTA CCA GCT TGA ATG CTG CTC CT, and the reverse 
primer was 5’-CTC GAG CGT GGG CAC GCT. The PCR products were separated by running 
8% nondenaturing polyacrylamide gel with 1X TBE (National Diagnostics) at 150 V for 30 min. 
The gel was post stained with ethidium bromide and subsequently imaged using Gel Doc XR+ 
system (Bio-Rad). The bands were quantified using ImageJ (NIH).  
Drug treatment in Drosophila. Fly lines bearing UAS-(CTG)60 and UAS-i(CTG)48054 
were kind gifts of Prof. Rubén Artero Allepuz (Universitat de València, Estudi General, Spain). 
The external eye and larval crawling assays were performed by Shaohong Peng and Prof. H. Y. 
Edwin Chan, The Chinese University of Hong Kong as previously described.49 
Determination of murine maximum tolerated dose (MTD). All experimental 
procedures were reviewed and approved by the University of Illinois Institutional Animal Care 
and Use Committee (Protocol #15232). Compound was formulated in sterile water and 
administered to C57BL/6 female mice (12-14 weeks old, Charles River) intraperitoneally for five 
consecutive days. All the mice were monitored over the course for signs of toxicity and weight 
loss. This experiment was performed by Hyang Yeon Lee, Prof. Paul J. Hergenrother, UIUC. 
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CHAPTER 4 
 IN VITRO SELECTION OF LIGANDS CAPABLE FORMING MORE POTENT 
AGENTS ON BOTH DNA/RNA TARGETS3 
4.1 Introduction 
Fragment-based drug discovery (FBDD)60 and target-guided synthesis (TGS)60-63 have 
emerged as promising approaches to discover new lead therapeutic agents. Both FBDD and TGS 
involve a suite of different strategies that share both conceptual and operational similarities, 
including the formation of tight binding ligands from smaller fragments. The most relevant to 
this work is the in situ TGS approach, wherein the target receptor serves as a template, binding 
two or more fragments in such a way that their reactive functional groups are in close proximity. 
This leads to an accelerated coupling reaction that produces a tighter binding ligand.  
The utilization of click chemistry has significantly accelerated the development of TGS. 
A number of tight-binding ligands for targeting proteins have been discovered in recent years 
using this technique.64,65 In contrast, the use of DNA and RNA targets with TGS has progressed 
more slowly. In 2003, Dervan and coworkers demonstrated the ability of DNA to catalyze the 
alkyne-azide [3+2] cycloaddition of hairpin polyamides, giving a heterodimeric product with a 
greater binding affinity and specificity.66 Click and native chemical ligation reactions between 
small molecules formed on DNA or RNA templates have been also reported by other groups,67-69 
however, the number of examples are few in comparison to protein targets.  
We are particularly interested in applying a TGS approach to both the DNA and RNA 																																																								
3 Some of the mateial in this chapter was adapted from the following publication: 
Luu, L. M.; Lee, J.; Nguyen, L.; Vergara, J. I.; Zimmerman, S. C. A Fragment-Based, Multi-target Drug Discovery 
Approach for Both DNA and RNA Targets Using a Template-Assisted Selection. (Manuscript in preparation) 
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targets causing DM1. The repetitive nature of dCTGexp and rCUGexp makes them well suited to 
FBDD. Specifically, we are intrigued by the discovery of dimeric ligands for DM1 reported by 
Miller and coworkers in 2008.70 They developed a bead-segregated, dynamic combinatorial 
library containing as many as 11,325 compounds equilibrated through a disulfide exchange 
reaction of 150 monomers. Among those dimeric ligands, the tightest binder was selected by a 
fluorescently labeled r(CUG)10. While this is a promising approach to discover new RNA binders 
in vitro, the high abundance of thiols in a cellular system makes the disulfide-containing 
compounds potentially unstable. 
Herein, we describe an approach that uses the template-assisted, irreversible alkyne-azide 
click reaction in a selection format with both d(CTG)16 and r(CUG)16 targets (Figure 20). A 
limited number of products were formed in each case and even fewer formed in both selections, 
suggesting this method can be useful for discovering both selective single and multi-target lead 
therapeutic agents.  
 
Figure 20. Illustration of the selection of multi-target agents using the click reaction templated by 
dCTG and rCUG repeats. (This image was obtained from Dr. Yugang Bai) 
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4.2. Design and Synthesis of the Clickable Compound Library  
To enable both FBDD and TGS to discover multi-target agents, initial focus was placed 
on ligands 1 and 4, which were rationally designed to selectively target dCTGexp or rCUGexp 
hairpin structures. The binding mechanisms of these ligands involve 1) specific recognition of 
the T-T and U-U mismatch by the triaminotriazine unit and 2) acridine intercalation (1) or 3) 
RNA binding by A-form RNA-bisamidinium groove complexation (4). Indeed, ligand 1 was 
reported to bind d(CTG)4 and r(CUG)4 with KD = 0.5 ± 0.2 µM and KD = 0.43 ± 0.11 µM, 
respectively.41 Ligand 4 shows strong affinity for r(CUG)12 (KD = 8 ± 2 µM) but no binding to 
dCTG repeats.45 As discussed in Chapter 2, an aminoalkyl substituted analog of 4, where the 
substituent is attached to the triaminotriazine moiety, binds both dCTG and rCUG repeats.49  
Over the past two decades, the alkyne-azide cycloaddition has been widely employed in 
bioconjugation, because of its excellent bioorthogonality.71,72 The small size of alkyne and azide 
groups makes them suitable for conjugating to both small- and macro-molecules. As discussed in 
chapter 2, a clickable moiety can be attached to the triaminotriazine ring of the bisamidinium 
containing ligands with minimal effect on binding to rCUGexp. Therefore, compounds 6a−c were 
included in the library, serving as clickable rCUG binders (Figure 21). In addition, the activated 
alkyne 24 was chosen with the expectation that it would undergo an accelerated click 
reaction.66,73 In addition to azides, amine 23 was employed to examine the potential of a Michael 
addition to the activated alkyne. For the acridine compounds, clickable functionality was 
conjugated to the acridine ring using an amide coupling reaction. Thus, ligands 25−32 containing 
side-chains of varying lengths and terminated with either an azide, amine, or alkyne group were 
prepared. In addition, it was found that replacing one triaminotriazine hydrogen in 1 with a 
methyl group weakens, but does not abolish its binding to a rCUG site.40 Thus, compound 31 
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containing a water-solubilizing aminopropyl group on the acridine ring and an N-azidopropyl 
group on the triaminotriazine recognition unit was prepared. The 5-atom linker in 32 was chosen 
based on our previous findings that compound 1 and an acridine-melamine conjugate with a 
pentyl linker have comparable binding affinities to rCUG repeats. Moreover, compound 32, 
which contains two amino groups, is water-soluble and potentially serves as a Michael donor for 
the activated alkyne ligands 24 and 25. It is note worthy that a derivative of 28 with an activated 
alkyne was found to undergo intramolecular Michael addition with a secondary amine.  
Generally, the clickable bisamidinium compounds 6a−c, and 23 were prepared as 
 
Figure 21. Structures of dCTG and rCUG binding ligands containing clickable groups. 
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described in the previous chapters. The N,N'-Dicyclohexylcarbodiimide (DCC)-promoted 
coupling reaction of amine 23 with propiolic acid afforded an electron-deficient alkyne 24. The 
general synthetic approach to acridine compounds 25−31 is outlined in Scheme 6. Thus, acridone 
3343 was treated with thionyl chloride, followed by the amide formation with corresponding 
amines to give acridine 34 in 54−88% yield. Substitution reaction of 34 and an amine-containing 
triaminotriazine in DMF gave desired acridine ligands in 21−73% yield. Additional steps were 
needed for the preparation of several other compounds (see the Synthesis section for details). 
Compounds 6a−c, 23−32 were isolated as either HCl or TFA salts, and were at least 95% pure as 
indicated by 1H NMR and analytical HPLC, except for 31 and 24 (93% and 86% pure, 
respectively).  
To increase both size and structural diversity, general DNA/RNA binders 35−59 were 
added to the library (Figure 22). Ligands 35 and 36 containing the bisamidinium core of 4 are 
potential major groove binder for A-form RNA,46 whereas acridines 38 an 39 are intercalators 
that do not contain the triaminotriazine recognition unit. Alkyne 37 contains a naphthrydine 
moiety, which was part of molecules targeting G-A and G-G mismatch DNA.74 Compound 40, a 
derivative of 5 with an azide chain, was obtained from Julio Serrano. Although binding modes of 
5 and 40 to dCTG and rCUG repeats remain to be elucidated, their tricyclic ring may insert 
Scheme 6. General synthesis of acridines 25−31. 
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Figure 22. Structures of general DNA/RNA binders 35−59 containing clickable groups. 
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between DNA/RNA base pairs, whereas the amino groups can interact with T-T or U-U 
mismatches through hydrogen bonds. Aminoglycosides 41−44, which are general RNA binders 
through electrostatic interactions, were prepared as previously reported.75 Generally, the Boc-
protected aminoglycosides underwent tosylation to convert the primary alcohol to a tosyl group, 
which was subsequently replaced by an azide. It was also found that neomycin B, kanamycin 
A/B, and amikacin bind various stem-loop mRNAs containing C-C, C-U, and A-A mismatch 
with nano to low micromolar KD.76 Interestingly, azide-containing kanamycin 41 can undergo the 
click reaction with an alkyne-bearing kanamycin in the presence of rCCUG repeats,67 whereas 
neomycin B 43 was found to inhibit the MBNL1-rCUGexp complex in vitro.29 Diazides 45−59 
were employed by the Hergenrother group as building blocks for the synthesis of 
deoxystreptamine dimers that selectively bound to RNA tetra- and octaloops with high affinity.76 
Although none of the diazides are known RNA binders, their aromatic structures resemble a 
number of known DNA and RNA intercalators or groove binders.77 Especially, 58 and 59 are 
derivatives of ethidium bromide, an intercalating agent. 
4.3 Design of the Selection Experiment 
The overall approach is shown schematically in Figure 23. Because the molecular weight 
of click products are higher than those of monomers, their presence can be easily detected using 
mass spectroscopy. In addition, most of the click products have distinct molecular weights, 
allowing MS peaks to be assigned to the corresponding clickable agents. When considering 
possible methods to monitor the templated click reactions, we chose matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS). In comparison to ESI-MS, MALDI 
generates less multiply charged ions and leads to fewer peaks in the spectrum of heterogeneous 
samples, making the data easier to analyze.78 Although MALDI-MS does not give a quantitative 
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assessment of the relative amount of each product formed, it has proven to be an excellent initial 
screen for assessing reaction conditions and degree of selectivity.  
In the selection experiment, equal molar amounts of all the compounds (25 µM) were 
incubated with the template d(CTG)16 or r(CUG)16 (12.5 µM) at 37 °C and pH 7.0 for various 
amounts of time. Before MALDI-MS analysis, DNA and RNA were degraded by DNase I and 
RNase A, respectively, to release tight binders. Parallel control experiments were performed 
under identical conditions but without template or with other nucleic acid sequences, including a 
standard 24-mer DNA duplex, a DNA duplex containing d(CTG)16-d(CAG)16, r(CCUG)8, 
r(CCCCGG)3, HIV-1 FS RNA, and tRNA (Figure 24). We anticipated that the d(CTG)16-
d(CAG)16 mainly exists as a fully paired DNA duplex. It was found that only 2% of the DNA 
containing 17 CTG-CAG repeats formed slipped-strand structures.79 The interest in the rCCUG 
 
Figure 23. Illustration of the MALDI-MS detection of DNA/ RNA template-assisted selection.  
Negative selection (top) indicates click products formed off-target, whereas cross-selection shows 
possible multi-target leads (red peaks) and single target agents (blue). 
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tetranucleotide repeat arises from its involvement in myotonic dystrophy type 2. Furthermore, 
both acridine and bisamidinium ligands structurally analogous to those studied here recognize 
rCCUG repeats selectively.80,81 In addition, a hexanucleotide repeat r(CCCCGG)3, an antisense 
RNA involved in c9FTD/ALS disease,82 is a potential target of the acridine-triaminotriazine 
compounds, based on the finding that compound 1 binds C-C mismatch with a KD value of 14 ± 
2 µM. On the other hand, the bisamidinium moiety in compound 6a−c, 23, 24, 35, and 36 was 
found to interact with HIV-1 FS RNA by hydrogen bonds. By using different DNA/RNA 
sequences, the selectivity of the clickable agents as well as the click products and the ability of 
this selection method to discover new lead agents for DNA/RNA-mediated diseases can be 
 
Figure 24. Structures of DNA/RNA sequences. 
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quickly accessed. 
4.4 Analysis of DNA/RNA Templated Click Selections by MALDI-MS 
The initial selection experiment involved 30 compounds, including 6a−c, 23−32, and 35, 
38, 45−59  (Figure 21 and 22). Considering that these compounds may undergo Michael addition 
or the alkyne-azide cycloaddition that may produce 1,4- and 1,5-adducts, there are 196 possible 
AB-type adducts and 5,219 ABA/ABC-type coupled products. The templated reactions of 
dialkyne-, diazide-, and diamine-containing bisamidinium ligands 6a−c, 23, 24 by d(CTG)16 and 
r(CUG)16, which can form 8 T-T and U-U mismatches, were expected to favor dimeric and 
trimeric products.  
In practice, the idealized results in Figure 23 were observed. Molecular weights of 
monomers are less than 713 Da, whereas those of dimers are between 716 and 1500 Da. As seen 
in Figure 25, no significant peaks corresponding to click products appeared after a 7 d incubation 
in the absence of RNA/DNA or in the presence of r(CCUG)8 or tRNA.  In the presence of a fully 
paired 24-mer DNA duplex or a paired DNA duplex containing d(CTG)16-d(GAC)16, small 
amounts of adducts were detected after 1 d.  
 In contrast, multiple intense peaks in the MALDI-MS were observed after just 1 d when 
the ligands were incubated with d(CTG)16 or r(CUG)16 and these peaks grew in intensity with 
additional time. Due to the observation of 6 peaks in both the DNA and RNA incubations, their 
corresponding structures were further characterized. Peaks at m/z 1027.4, 1084.4, 1215.6 were 
identified as the click product of 25+26, 25+31, and 25+6c, respectively (Figure 26). Some click 
products could not be positively identified because the MALDI-MS m/z was consistent with 
more than one product.  Thus, the peak at m/z 1041.4 could arise from three different click 
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Figure 25. Representative MALDI-MS of templated click reactions of 6a−c, 23−32, and 35, 38, 
45−59. Analyzed samples were crystallized in 2,5-dihydroxybenzoic acid (DHB) matrix. MALDI-MS 
were obtained from the Mass Spectrometry Laboratory, UIUC. The selections were performed in 
triplicate. The spectra were formatted using Adobe Illustrator CS6. 
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couplings: 25+27, 6b+35, or 24+50.  Likewise, the peak at m/z 1099.5 could correspond to 
25+32 or 6a+26 and the peak at m/z 1141.5 to 25+28 or 6b+26.  
Template selection assays under the same conditions as above with 6a, 6b, 6c, 26, 27, 35, 
50, but omitting 25 did not produce any click products after 7 d (Figure 27). This result suggests 
that the formed adducts at m/z 1041.4, 1099.5, 1141.5 are from the following pairings: 25+27, 
25+32, and 25+28, respectively (Figure 26). Not only does the template-assisted coupling appear 
quite selective, with only six major products formed, all six contain the same acridine-based 
alkyne partner 25, presumably reflecting the higher reactivity of the activated alkyne. The 
selection also shows a considerable degree of selectivity with respect to the azide partner as five 
of the six participating azides (26−28, 31, and 32) are acridine-triaminotriazine conjugates.  
Indeed, only the compound at m/z 1215.6 was the product of acridine 25 and bisamidinium 
ligand 6c.   
 
Figure 26. Matching the MALDI-MS peaks to the r(CUG)16-templated click products.  
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It is important to note that the relative intensity of these peaks varies between runs, but 
remains the primary products of the in situ template click reaction as detected by MALDI-MS in 
independent selections. These results suggest that binding affinity and alkyne reactivity is the 
 
Figure 27. MALDI-MS of the mixture of 6a−c, 26, 27, 35, 50 in the presence of d(CTG)16 (top) and 
r(CUG)16 (bottom) after 7 d incubation at 37 °C, pH 7.0. MALDI-MS were obtained from the Mass 
Spectrometry Laboratory, UIUC. 
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main determinant of the selection process. The apparent lack of a requirement for precise 
positioning of the alkyne and azide also supports this conclusion. Thus, the increasingly longer 
chain connecting the azide to the acridine ring along the series 26 → 27 → 28 did not affect the 
ability of the click product to form. Liu and coworkers reported an extensive series of distance-
independent, DNA-templated synthetic reactions, to which they attributed hybridization kinetics 
being rate determining in many instances.83,84 Although the dataset here is not expansive enough 
to reach firm conclusions, these examples show that there does not appear to be a strict distance 
or geometric requirement for the template-assisted click reaction. 
As discussed above, only known rCUG binding molecules participated in the templated 
click reaction. In addition, no products from the Michael addition of amine-containing 
compounds and activated alkynes were observed. Therefore, to allow other ligands to bind rCUG 
repeats, amine- and azide-containing ligands 23, 26, 28−32 were excluded in another selection 
experiment. On the other hand, the second selection included more general DNA/RNA binders, 
including electron-deficient alkynes 36, 37, 39, azide 40, and aminoglycosides 41−44. After 2 
days of incubation with DNA or RNA, reaction samples were mixed with either 2,5-
dihydroxybenzoic acid (DHB), or α-cyano-4-hydroxycinnamic (CHCA), and analyzed using a 
positive mode. Using DHB matrix, distinct peaks were observed in different samples (Figure 28). 
A small peak corresponding to the click product of 25 and 27 was observed in the reactions with 
r(CUG)16, 24mer-DNA, and r(CCUG)12. Although the incubation with d(CTG)16 showed an 
intense peak of 25+27 at 1041 in DHB matrix, this peak did not appear in CHCA matrix, 
suggesting the advantage of DHB over CHCA in detecting this kind of small molecules.  Peaks 
from 800 to 1500 seen in r(CCCCGG)3, HIV-1 FS RNA, and tRNA matched with those from the 
degradation of RNA using RNase A, and therefore not identified (Figure 28 and 29). 
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Figure 28. MALDI-MS of the selection experiment containing 6a−c, 24, 25, 27, and 35−59 after 2 d 
using DHB matrix. The mass spectra were formatted using Adobe Illustrator CS6. 
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Figure 29. MALDI-MS of the selection experiment containing 6a−c, 24, 25, 27, and 35−59 after 2 d 
using CHCA matrix. The mass spectra were formatted using Adobe Illustrator CS6. 	
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4.5 Analysis of Click Reaction of 25 and 27 Using HPLC 
A more quantitative view of the RNA-templated click reaction was obtained using HPLC 
analysis, which is capable of monitoring the consumption of reactants, and the formation of 
product (Figure 30a). Alkyne 25 and azide 27 were chosen for this experiment because their 
click product was regularly one of the most predominant peaks observed across all of the 
MALDI-MS selection assays. To obtain detectable signals in HPLC, concentrations of both 
ligands and r(CUG)16 were raised to 100 µM and 25 µM, whereas the pH and salt concentration 
held constant to those in the selection experiment. As seen in Figure 30a, compounds 25 and 27 
were rapidly consumed, and a peak corresponding to the click product was observed after 1 d. In 
contrast, the size of the HPLC peak corresponding to alkyne 25 and azide 27 remained minimally 
changed after 5 d in the absence of r(CUG)16. By using an internal standard in the HPLC 
analysis, the consumption of alkyne 25 was quantitatively determined (Figure 30b). In the 
presence of r(CUG)16, ca. 40% of 25 remained after 1 d, and both reactants were almost 
consumed after 4 d. Without the RNA template, only 20% of 25 reacted with the azide after 5 d.  
The [3+2] cycloaddition of 25 and 27 can produce 1,4- and 1,5-disubstituted 1,2,3-
triazole products. The 1,4-isomer 60, prepared using a system containing copper (II), sodium 
Scheme 7. Synthesis of dimer 60. 
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Figure 30. (a) Monitoring the reaction of 25 and 27 in the presence (left) and absence (right) of 
r(CUG)16. Internal standard (compound 28) was marked as an asterisk. (b) The consumption of 25 in the 
presence (blue diamond) and absence (red square) of r(CUG)16. The error bars were obtained from two 
independent experiments. (c) Determination of the click product isomer by HPLC. 
	 65 
ascorbate and TBTA (Scheme 7), served as the authentic sample in the HPLC analysis. It was 
found that the RNA-templated click reaction mainly affords 1,4-isomer (Figure 30c). In fact, the 
thermal cycloaddition of azide and electron deficient acetylene favors the formation of 1,4-
isomer.66 
4.6 Biological Activities of the Click Product 
4.6.1 Inhibition of the Transcription of dCTG Repeats In Vitro  
The transcription inhibition of dCTG repeats has emerged as a potential therapeutic 
strategy to treat DM1 in recent years. Pearson et al. discovered that 67−70% of the DNA 
containing 50 dCTG-dCAG repeats exist as slipped-strand conformations, in which dCTG and 
 
Figure 31. In vitro transcription inhibition of d(CTG)74-d(GAC)74 by monomers 25, 27, and dimer 60 at 
37 °C, pH 8.3. (a) Representative transcription gels. The reaction mixture was separated on a 8% 
denaturing PAGE gel. (b) Plot of the normalized level of r(CUG)74 transcript versus concentration of 
ligands. Error bars represent the standard error of mean from three independent experiments. The 
intensity of rCUG product was normalized to HIV-1 FS RNA as an internal standard. To access the 
transcription inhibition potency, the ratio of r(CUG)74/HIV-1 FS RNA in the ligand-treated sample was 
compared with that from the untreated one. (This experiment was conducted by JuYeon Lee) 
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dCAG repeats form hairpin and unpaired loop structures, respectively.79,85 Recently, we49,86 and 
Berglund36,37 reported that targeting DNA with a dCTG binding ligand could inhibit the 
transcription to form rCUG repeats both in vitro and in DM1 model cells.  
To determine whether compound 60, that was discovered from the dCTG template-
mediated selection, could function in this manner, the linearized T7-promoter containing 
(CTG)74 plasmids were incubated with 60, followed by the in vitro transcription reaction with T7 
polymerase.13,49 For comparison, the transcription inhibition by monomers 25 and 27 was also 
performed under similar conditions. The rCUG transcript and HIV-1 FS RNA (internal standard) 
were stained with ethidium bromide (EtBr). It was found that incubation of the dimeric ligand 60 
at 5−7.5 µM with the d(CTG)74 template resulted in more than 90% suppression of the 
 
Figure 32. In vitro transcription inhibition of the control DNA by monomers 25, 27, and dimer 60. (a) 
Representative transcription gels. (b) Plot of the normalized level of r(CUG)74 transcript versus 
concentration of ligands. Error bars represent the standard error of mean from three independent 
experiments. (This experiment was conducted by JuYeon Lee) 
	 67 
production of CUG-RNA, whereas treatment with monomeric ligands 25 and 27 in 
concentrations up to 10 µM only slightly reduced the r(CUG)74 levels (Figure 31). Although 
monomers exhibited a nearly complete transcription inhibition at 75 µM, this study indicates an 
improved potency of dimer 60 at a low micro-molar concentration. However, it was found that 
dimer 60 also inhibited 34−50% of transcription of the control DNA duplex at 5−7.5 µM (Figure 
32). In fact, a small amount of dimer 60 was also observed in the selection experiment involving 
fully paired DNA sequences. 
4.6.2 Inhibition of the MBNL1-rCUGexp In Vitro 
Because dimer 60 was formed in both dCTG and rCUG templated click reaction, the 
ability of 60 as well as alkyne 25 to inhibit the MBNL1 sequestration by rCUGexp was evaluated 
using EMSA. In this experiment, the truncated MBNL1 and radiolabeled-r(CUG)12 formed a 
tight complex with a KD value of 9 ± 1 nM. An IC50 value of 26000 ± 2000 nM and a calculated 
KI of 3343 ± 452 nM were determined for monomer 25, whereas dimer 60 was ca. 144-fold more 
potent, with IC50 and KI values of 180 ± 5 nM and 23 ± 3 nM, respectively (Figure 33).  
The improvement in inhibition potency of 60 is likely a result of its enhanced binding to 
both d(CTG)16 and r(CUG)16. Both compounds 25 and 60 are fluorescent and have an observable 
fluorescence intensity decrease upon binding to DNA/RNA (Figure 34). Thus, the apparent 
binding constants for complexation to d(CTG)16, and r(CUG)16 were determined using a reverse 
fluorescence titration (Figure 35). It was found that the binding affinities of alkyne 25 to 
d(CTG)16 and r(CUG)16 were 4810 ± 314 nM and 350 ± 27 nM, respectively, which are similar 
to KD values of 1 determined by ITC.40,41 In comparison to 25, dimer 60 exhibited ca. 21- and 
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15-fold stronger affinities to d(CTG)16 (KD = 23 ± 1 nM) and r(CUG)16 (KD = 230 ± 10 nM). 
Apart from the increased binding affinities, the improved inhibition potency of 60 may in part 
result from the steric hindrance of the triazole linker. 
4.7 Conclusions and Outlook 
Herein, we have described an accelerated strategy for discovering agents that target the 
DNA and RNA that cause myotonic dystrophy type 1 (DM1). The approach combines elements 
of FBDD and TGS with a positive cross screen to discover dual-targeting lead agents for DM1. 
 
Figure 33. Inhibition of MBNL1-r(CUG)12 by (a) monomer 25 and (b) dimer 60 by EMSA. Left: 
Representative EMSA gel. The compound concentration was serially diluted by the factor of 2. Right: 
Determination of the IC50 value. The points at 250 µM of 25 and 5 µM of 60 were not included in the 
plot because of aggregation in some gels. Standard error of the mean was obtained from three 
independent experiments. All data were plotted and fitted using Prism. 
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Template-assisted selections produced only a small number of products that formed only 
 
Figure 34. Fluorescence spectra of 25 and 60 as the r(CUG)16 solution was titrated to the ligand 
solutions. 
	
Figure 35. Determination of binding affinities of 25 (top) and 60 (bottom) to r(CUG)16 and d(CTG)16. 
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in the presence of the target DNA or RNA and not with other oligonucleotides, such as tRNA 
and a generic dsDNA.  The selection appeared to favor tighter binding ligands and those with 
more reactive clickable functionality (i.e., activated alkyne) and was less discriminating with 
respect to the length of the linker between the ligand and the click-functional group.  
 Beyond the general approach described here for the discovery of more potent in vitro 
inhibitors and multi-targeting agents, this same general protocol could be applied to DM1 cells. 
A cell-based approach adds variables of cellular and nuclear permeability, critical aspect for drug 
development, to the selection. More importantly, it opens the prospect of a self-assembling 
therapeutic strategy using smaller molecules whose improved pharmacokinetic properties allow 
them to reach the target, which then facilitates the synthesis of the active agent.67,87 Such an 
approach will require a new method of product analysis and a faster biocompatible click 
reaction. Efforts to accomplish these goals are currently underway. The success of the templated-
click selection using the toxic RNA in DM1 suggests that it may have applications to other 
diseases caused by unstable trinucleotide repeats such as Huntington’s disease, fragile X 
syndrome, and Friederich’s ataxia. 
4.8 Materials and Methods 
4.8.1 Synthesis 
            
Compound 62: Using the similar procedure as described in Chapter 2, 2.9 g (17.6 mmol) 
of 7, 3 mL (21.5 mmol) of Et3N, and 3.1 g (19.3 mmol) of N-Boc-ethylenediamine 61 afforded 
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3.75 g (74%) of 62 as a white solid. 1H NMR (DMSO-d6): δ 7.65−7.50 (m, 1H), 7.31−7.11 (m, 
2H), 6.85−6.81 (m, 1H), 3.25−3.20 (m, 2H), 3.07−3.01 (m, 2H), 1.36 (s, 9H). Note: N-Boc-
ethylenediamine 61 is available from Sigma-Aldrich or can be easily prepared using reported 
procedures. 
          
Compound 63: Using the similar procedure as described above, 3.13 g (10.8 mmol) of 62, 
5.5 mL (54.7 mmol) of 1,4-diaminobutane 10 afforded 2.51 g (68%) of 63 as a white solid. 1H 
NMR (DMSO-d6): δ 6.8 (s, 1H), 6.53−5.88 (m, 4H), 3.24−3.02 (m, 8H), 1.88 (s, 2H), 1.75 (s, 
2H), 1.37 (s, 9H). 
 
Compound 23: To a 200 mL 24/40 one neck round bottom flask was added 1.0 g (3.44 
mmol) of 12. The solid was suspended in 30 mL of anhydrous EtOH. To the white suspension 
was added 1.2 mL (8.6 mmol) of anhydrous Et3N. To the obtaining clear solution was added 2.9 
g (8.2 mmol) of 63 in 5 mL of anhydrous EtOH. The mixture was stirred at room temperature 
overnight. Ethanol was removed using a rotary evaporator. The crude was dissolved in 50 mL of 
ethanolic solution of HCl 2 M. The reaction was stirred at room temperature overnight. The 
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solution was concentrated using a rotary evaporator. The crude was purified by Sephadex CM-25 
column using aqueous solution of NH4HCO3 (gradient from 0.3 M to 1 M). Fractions containing 
products were combined, concentrated using a rotary evaporator to give 1.23 g (59%) of 23 as a 
white solid. The solid was dissolved in a methanolic solution of HCl, then concentrated to give a 
white HCl salt. 1H NMR (DMSO-d6): δ 10.22 (s, 2H), 9.77 (s, 2H), 9.38 (s, 2H), 8.15 (s, 4H), 
7.97(s, 4H), 6.84−6.65 (m, 4H), 6.31−6.09 (m, 4H), 3.48−3.46 (m, 4H), 3.38−3.34 (m, 4H), 3.24 
(s, 4H), 2.91 (s, 4H), 1.69−1.57 (m, 8H). HR-ESI-MS (m/z) calculated for [M + H]+: 609.4075; 
found 609.4071.  
 
Compound 24: To a 15 mL 14/20 round bottom flask was added 207 mg (0.25 mmol) of 
23. The solid was dissolved in 0.5 mL of DI water and 3 mL of DMF. The mixture was stirred at 
room temperature for 5 min. To a 5 mL vial was added 516 mg (2.50 mmol) of DCC, and 2 mL 
of CH2Cl2. To the resulting solution was added slowly 181 mg (2.58 mmol) of propiolic acid 64. 
The resulting brown suspension was added to the reaction flask at once. The reaction was stirred 
at room temperature for 30 min. The mixture was diluted with 10 mL of water and 8 mL of 
CH2Cl2, and mixed thoroughly. The aqueous layer was isolated, extracted with 10 mL of CH2Cl2 
one more time. The aqueous layer was purified by C18 column chromatography using a 
CombiFlash with 0.1% of HCl in MeOH/H2O (1/9, v/v) at a flow rate of 5 mL/min. The fractions 
containing product was combined, and concentrated using a rotary evaporator to give 132 mg 
(51%) of 24 as a tetra-HCl salt.  1H NMR (DMSO-d6): δ 10.27−10.20 (m, 2H), 9.80 (s, 2H), 
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9.44−9.41 (m, 2H), 8.93−8.83 (m, 2H), 8.50−7.91 (m, 12H), 4.18 (s, 2llH), 3.49−3.46 (m, 4H), 
3.39−3.33 (m, 8H), 3.27−3.25 (m, 4H), 1.71−1.63 (m, 8H). 13C NMR (DMSO-d6): δ 161.74, 
155.92, 151.99, 151.95, 132.93, 128.69, 128.66, 78.25, 75.99, 75.92, 48.61, 42.54, 42.47, 39.52, 
38.32, 26.00, 24.65. HR-ESI-MS (m/z) calculated for [M + H]+: 713.3973; found 713.3950. 
HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 4.7 min (86%). 
 
Compound 66: To a 300 mL round bottom flask was added 7.35 g (36.2 mmol) of 65 and 
100 mL of CH3CN. To the reaction flask was added slowly 5 ml (42.0 mmol) of ethyl 
trifluoroacetate over 5 h at 80 °C. The mixture was stirred at 80 °C for an additional 1 h. The 
solvent was removed using a rotary evaporator. The crude was purified by silica gel column 
chromatography with a gradient mixture of CH2Cl2/MeOH from 19/1 to 9/1 (v/v). The fractions 
containing product were combined and concentrated to give 6.1 g (56%) of 66 as a pale yellow 
oil. 1H NMR (DMSO-d6): δ 3.32−3.28 (m, 6H), 3.14−3.10 (m, 2H), 2.65−2.63 (m, 2H), 1.38 (s, 
9H). ESI-MS (m/z) calculated for [M + H]+: 300.2; found 300.1. 
 
Compound 35a: To a 100 mL 14/20 one neck oven-dried round bottom flask was added 
3.1 g (9.2 mmol) of acridone 34. The solid was dissolved in 20 mL of SOCl2 and 1 mL of 
anhydrous DMF. The mixture was stirred at 80 °C for 30 min. Thionyl chloride was removed by 
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distillation. The crude was dissolved in 30 mL of anhydrous CH2Cl2, the solvent was removed by 
distillation. This step was repeated two times. The yellow solid was dried under high vacuum for 
at least 1 hour. The flask was placed in an ice bath. The yellow solid was dissolved by 50 mL of 
anhydrous CH2Cl2. To the resulting solution was added anhydrous Et3N until pH 11. To the 
reaction mixture was added 2.0 g (11.5 mmol) of N-Boc-1,3-propanediamine. The temperature 
was raised slowly to 25 °C, and the mixture was stirred overnight. The reaction was concentrated 
using a rotary evaporator. The crude was purified by silica gel column chromatography using a 
gradient mixture of CH2Cl2/MeOH from 100:0 to 19:1 (v/v). Fractions containing product were 
combined, concentrated using a rotary evaporator to give 3.2 g (84%) of compound 35a as a 
yellow solid. 1H NMR (CDCl3): δ 11.75 (s, 1H), 9.00 (dd, J = 7.5, 1.5, 1H), 8.65−8.63 (m, 1H), 
8.47 (d, J = 8.5, 1H), 8.32 (d, J = 8.7, 2H), 7.91−7.87 (m, 1H), 7.78−7.74 (m, 1H), 7.73−7.70 (m, 
1H), 5.19 (s, 1H), 3.75 (q, J = 6.3, 2H), 3.34 (q, J = 6.3, 2H), 1.95 (quint, J = 6.4, 2H), 1.46 (s, 
9H).  
Compound 35b: Using the similar procedure as described above, 1.0 g (3.0 mmol) of 
acridone 34 and 450 mg (4.5 mmol) of 3-azido-propylamine gave 898 mg (88%) of 35b as a 
yellow solid. 1H NMR (CD3OD-d4): δ 8.52 (dd, J = 7.0, 1.4, 1H), 8.18 (dd, J = 8.6, 1.5, 1H), 
8.06−8.04 (m, 1H), 7.81−7.78 (m, 1H), 7.75−7.71 (m, 1H), 7.55−7.47 (m, 2H), 3.63 (t, J = 6.8, 
2H), 3.56 (t, J = 6.6, 2H), 2.02 (quint, J = 6.7, 2H).  
Compound 35c: Using the similar procedure as described above, 5.15 g (15.3 mmol) of 
acridone 34 and 2.65 g (23.2 mmol) of 4-azido-butylamine gave 3.75 g (69%) of 35c as a yellow 
solid. 1H NMR (CD3OD-d4): δ 8.47 (dd, J = 7.1, 1.5, 1H), 8.07 (dd, J = 8.6, 1.5, 1H), 7.95 (dt, J 
= 8.7, 1.0, 1H), 7.69−7.64 (m, 2H), 7.50−7.41 (m, 2H), 3.56−3.45 (m, 4H), 1.85−1.77 (m, 4H). 
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Compound 35d: Using the similar procedure as described above, 3.0 g (8.9 mmol) of 
acridone 34 and 3.46 g (10.64 mmol) of 66 gave 2.57 g (54%) of 35d as a yellow solid.  
 
Compound 67: To a 100 mL round bottom flask was added 1.53 g (3.7 mmol) of 35a, 
0.95 g (4.8 mmol) of 17, 20 mL of DMF, and 0.9 mL (5.2 mmol) of DIPEA. The mixture was 
stirred at 80 °C in an oil bath for 3 h. The reaction was concentrated using a rotary evaporator. 
The crude was purified by basic Al2O3 column chromatography with a gradient mixture of 
CH2Cl2/MeOH from 100/0 to 90/10 (v/v). Fractions containing product were combined and 
concentrated using a rotary evaporator. The yellow solid was dissolved in a mixture of 50 mL of 
TFA and 50 mL of CH2Cl2. The mixture was stirred at room temperature for 5 h. The reaction 
was concentrated using a rotary evaporator, the crude was dried under high vacuum to give 1.68 
g (56%) of 67 as a yellow solid. 1H NMR (CD3OD-d4): δ 8.70 (d, J = 8.6, 1H), 8.52 (d, J = 8.7, 
1H), 8.46 (d, J = 7.3, 1H), 7.99 (m, 1H), 7.90 (d, J = 8.4, 1H), 7.64−7.59 (m, 2H), 4.21 (t, J = 
7.3, 2H), 3.63 (t, J = 6.7, 2H), 3.45 (t, J = 6.6, 2H), 3.09 (t, J = 7.5, 2H), 2.06 (m, 4H), 1.78 (m, 
2H). ESI-MS (m/z) calculated for [M + H]+: 475.3; found 475.1.  
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Compound 25: To a 50 mL centrifuge tube containing 30 mL of anhydrous DMF was 
added 1.50 g (7.3 mmol) of DCC. To the resulting solution was added 0.47 g (6.7 mmol) of 
propiolic acid 64. The mixture was vortexed until the suspension was formed. The solid was 
filtered, the filtrate was transferred to a 200 mL round bottom flask. To the separate 50 mL 
centrifuge tube was added 1.05 g (1.3 mmol) of 67, 20 mL of anhydrous DMF, and 1 mL (7.2 
mmol) of anhydrous Et3N. The resulting suspension was added to the reaction flask slowly. The 
reaction was stirred at room temperature for 30 min. The mixture was concentrated using a rotary 
evaporator. The crude was purified by C18 column chromatography using a gradient mixture of 
H2O/MeOH from 100/0 to 50/50 (v/v) with 0.1% TFA. Fractions containing product were 
combined and concentrated using a rotary evaporator to give 0.55 g (57%) of 25 as a yellow TFA 
salt. 1H NMR (CD3OD-d4): δ 8.64 (dd, J = 8.7, 2.3, 1H), 8.49 (dd, J = 8.8, 2.7, 1H), 8.39 (dd, J = 
7.4, 2.3, 1H), 7.99−7.95 (m, 1H), 7.90 (dd, J = 8.6, 2.3, 1H), 7.61−7.56 (m, 2H), 4.20 (dt, J = 
7.3, 2.7, 2H), 3.63 (d, J = 3.2, 1H), 3.56 (dt, J = 6.8, 2.7, 2H), 3.44 (dt, J = 6.7, 2.9, 2H), 3.38 (dt, 
J = 6.9, 2.8, 2H), 2.05 (quint, J = 8.0, 2H), 1.92 (dquint, J = 6.8, 2.6, 2H), 1.77 (quint, J = 7.2, 
2H). HR-ESI-MS (m/z) calculated for [M + H]+: 527.2631; found 527.2635. HPLC (0.1% TFA 
in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 7.5 min (100%). 
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Compound 26: To a 100 mL round bottom flask was added 201 mg (0.59 mmol) of 35b, 
142 mg (0.71 mmol) of 17, 10 mL of DMF, and 0.15 mL (0.86 mmol) of DIPEA. The mixture 
was stirred at 80 °C in an oil bath for 2 h. The reaction mixture was concentrated using a rotary 
evaporator. The crude was purified by basic Al2O3 column chromatography using a gradient 
mixture of CH2Cl2/MeOH from 100/0 to 90/10 (v/v). Fractions containing product were 
combined and concentrated using a rotary evaporator to give a yellow solid. The solid was re-
purified by C18 column chromatography using a gradient mixture of H2O/MeOH from 90/10 to 
80/20 (v/v) with 0.1% TFA at a flow rate of 5 mL/min. Fractions containing product was 
combined and concentrated using a rotary evaporator to give 271 mg (63%) of compound 26 as a 
yellow TFA salt. 1H NMR (CD3OD-d4): δ 8.63 (s, 1H), 8.46 (dd, J = 8.6, 1.5, 1H), 8.31 (d, J = 
8.7, 1H), 7.93−7.91 (m, 1H), 7.72 (t, J = 7.5, 1H), 7.41−7.37 (m, 2H), 3.92 (t, J = 7.1, 2H), 3.69 
(t, J = 6.7, 2H), 3.55 (t, J = 6.6, 2H), 3.29 (t, J = 6.9, 2H), 2.04 (quint, J = 6.7, 2H), 1.85 (quint, J 
= 7.6, 2H), 1.62 (quint, J = 7.4, 2H). HR-ESI-MS (m/z) calculated for [M + H]+: 501.2587; found 
501.2593. HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 17.8 min 
(100%). 
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Compound 27: Using the similar procedure as described above, 3.75 g (10.6 mmol) of 
35c and 2.15 g (10.9 mmol) of 17 gave 5.57 g (71%) of 27 as a yellow TFA salt. 1H NMR 
(CD3OD-d4): δ 8.65 (dd, J = 8.6, 1.2, 1H), 8.49 (d, J = 8.6, 1H), 8.41 (dd, J = 7.4, 1.2, 1H), 
7.99−7.96 (m, 1H), 7.87 (dd, J = 8.6, 1.1, 1H), 7.61−7.56 (m, 2H), 4.20 (t, J = 7.2, 2H), 3.54 (t, J 
= 6.9, 2H), 3.44 (t, J = 6.6, 2H), 3.40 (t, J = 6.7, 2H), 2.08 −2.02 (m, 2H), 1.82−1.69 (m, 6H). 
HR-ESI-MS (m/z) calculated for [M + H]+: 515.2744; found 515.2741. HPLC (0.1% TFA in 
H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 26.4 min (100%). 
 
Compound 68: To a 100 mL round bottom flask was added 2.57 g (4.8 mmol) of 35d, 
1.51 g (5.6 mmol) of N2-(4-aminobutyl)-1,3,5-triazine-2,4,6-triamine hydrochloride salt 17, 50 
mL of DMF, and 3.3 mL (23.7 mmol) of Et3N. The mixture was stirred at 80 °C in an oil bath for 
3 h. The reaction mixture was concentrated using a rotary evaporator. The crude was purified by 
silica gel column chromatography using a gradient mixture of CH2Cl2/MeOH from 19:1 to 4:1 
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(v/v). Fractions containing product were combined and concentrated using a rotary evaporator. 
The yellow solid was dissolved in 50 mL of MeOH. To the reaction solution was added slowly 
10 g of pellet NaOH. The reaction was stirred at room temperature overnight. The reaction was 
concentrated using a rotary evaporator. The crude was purified by silica gel column 
chromatography using a gradient mixture of CH2Cl2/MeOH from 19:1 to 4:1 (v/v). Fractions 
containing product were combined, concentrated using a rotary evaporator, and dried under high 
vacuum to give 2.1 g (73%) of 68 as a yellow solid. 
  
Compound 28: To a 100 mL 14/20 1 neck round-bottom flask was added 110 mg (0.18 
mmol) of 68 and 5 mL of CH2Cl2. The flask was placed in an ice bath. A mixture of 130 mg 
(0.63 mmol) of DCC and 95 mg (0.57 mmol) of 4-bromobutanoic acid 69 was dissolved in 5 mL 
of CH2Cl2. The resulting suspension was added to the reaction flask at once. The reaction was 
stirred at 0 °C for 1 h. The solvent was removed using a rotary evaporator. To the reaction flask 
was added 400 mg (6.15 mmol) of NaN3. The solid was dissolved in 10 mL of DMF. The 
suspension was stirred at 80 °C in an oil bath for 3 h. The mixture was concentrated using a 
rotary evaporator. The crude was dissolved in a mixture containing 15 mL of TFA and 15 mL of 
CH2Cl2. The solution was stirred at room temperature for 3 h. The reaction was concentrated 
using a rotary evaporator. The crude was purified by C18 column chromatography using 0.1% 
TFA in H2O/MeOH mixture (8:2, v/v), at a flow rate of 10 mL/min. Fractions containing product 
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were combined, concentrated using a rotary evaporator, and dried under high vacuum to give 
product 90 mg (51%) of 28 as a yellow TFA salt. 1H NMR (CD3OD-d4): δ 8.71 (dd, J = 8.6, 0.6, 
1H), 8.53−8.48 (m, 2H), 8.03−7.98 (m, 2H), 7.65−7.60 (m, 2H), 4.21 (t, J = 7.3, 2H), 3.85 (t, J = 
5.4, 2H), 3.53 (t, J = 5.4, 2H), 3.45 (t, J = 6.6, 2H), 3.38 (t, J = 5.4, 2H), 3.25 (t, J = 5.4, 2H), 
3.15 (t, J = 6.8, 2H), 2.23 (t, J = 7.5, 2H), 2.06 (quint, J = 7.4, 2H), 1.77 (quint, J = 7.2, 2H), 
1.63 (quint, J = 7.1, 2H). HR-ESI-MS (m/z) calculated for [M + H]+: 615.3380; found 615.3380. 
HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 6.5 min (100%). 
 
Compound 30: To a 25 mL 14/20 1 neck round bottom flask was added 95 mg (0.16 
mmol) of 68. The solid was dissolved in a mixture of 5 mL of TFA and 5 mL of CH2Cl2. The 
mixture was stirred at room temperature for 3 h. Solvents were removed using a rotary 
evaporator, and dried overnight to give 138 mg (91%) of compound 30 as a yellow TFA salt. 1H 
NMR (CD3OD-d4): δ 8.69 (dd, J = 8.6, 1.2, 1H), 8.52−8.48 (m, 2H), 8.02−7.98 (m, 1H), 7.91 
(dd, J = 8.6, 1.1, 1H), 7.60 (t, J = 8.0, 2H), 4.2 (t, J = 7.2, 2H), 3.89 (t, J = 5.5, 2H), 3.51−3.38 
(m, 8H), 2.05 (quint, J = 7.3, 2H), 1.77 (quint, J = 7.3, 2H). HR-ESI-MS (m/z) calculated for [M 
+ H]+: 504.2948; found 504.2942. HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 
mL/min): t = 5.0 min (100%). 
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Compound 29: To a 50 mL 14/20 round bottom flask was added 111 mg (0.22 mmol) of 
27. The yellow solid was suspended in 10 mL of THF and 1 mL of DI water. To the stirred 
reaction mixture was added 68 mg (0.26 mmol) of PPh3 in several portions over 1 h. The mixture 
was stirred at room temperature overnight. The mixture was concentrated using a rotary 
evaporator. The crude was purified by C18 column chromatography using 0.1% TFA in 
H2O/MeOH (8/2, v/v). The fractions containing product was combined, concentrated using a 
rotary evaporator to give 95 mg (53%) of 29 as a yellow TFA salt. 1H NMR (CD3OD-d4): δ 8.68 
(dd, J = 8.7, 1.2, 1H), 8.52 (d, J = 8.5, 1H), 8.44 (dd, J = 7.5, 1.2, 1H), 8.02−7.99 (m, 1H), 7.89 
(dd, J = 8.6, 1.1, 1H), 7.63−7.59 (m, 2H), 4.21 (t, J = 7.2, 2H), 3.58−3.55 (m, 2H), 3.45 (t, J = 
6.6, 2H), 3.04−3.01 (m, 2H), 2.05 (quint, J = 7.5, 2H), 1.82−1.74 (m, 6H). HR-ESI-MS (m/z) 
calculated for [M + H]+: 489.2839; found 489.2840. HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), 
flow rate = 3 mL/min): t = 5.5 min (100%). 
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Compound 31: Using the similar procedure described above, 219 mg (0.53 mmol) of 35a, 
and 179 mg (0.64 mmol) of 11c gave 238 mg (50%) of 31 as a yellow TFA salt. 1H NMR 
(CD3OD-d4): δ 8.69 (d, J = 8.6, 1H), 8.51 (d, J = 8.7, 1H), 8.47 (d, J = 7.5, 1H), 7.99 (t, J = 7.7, 
1H), 7.88−7.86 (m, 1H), 7.62−7.57 (m, 2H), 4.22 (q, J = 6.5, 2H), 3.63 (t, J = 6.7, 2H), 
3.50−3.29 (m, 6H), 3.10 (t, J = 7.4, 2H), 2.10−2.03 (m, 4H), 1.85−1.72 (m, 4H). HR-ESI-MS 
(m/z) calculated for [M + H]+: 558.3166; found 558.3162. HPLC (0.1% TFA in H2O/MeOH (1:1, 
v/v), flow rate = 3 mL/min): t = 9.0 min (93%). 
 
Compound 72: To a 100 mL 24/40 round bottom flask was added 15.5 g (103.5 mmol) of 
tris(2-aminoethyl)amine 71, and 30 mL of MeOH. The reaction flask was placed in an oil bath 
and heated to 100 °C. To the reaction flask was added 3.15 g (21.6 mmol) of 2-chloro-4,6-
diamino-1,3,5-triazine 70 slowly over 30 min. The reaction was stirred at 100 °C for 30 min. The 
reaction was concentrated using a rotary evaporator. The residue was suspended in 200 mL of 
acetone. The solid was filtered, purified by C18 column chromatography using 0.1 % TFA in 
H2O/MeOH mixture (9:1, v/v) at a flow rate of 5 mL/min. Fractions containing product were 
combined, concentrated using a rotary evaporator to give 3.75 g (68%) of 72 as a white TFA salt. 
1H NMR (DMSO-d6): δ 8.20−7.85 (m, 11H), 3.39−3.35 (m, 2H), 2.91 (br s, 4H), 2.69 (t, J = 5.7, 
4H), 2.60 (t, J = 6.3, 2H). LR-ESI-MS (m/z) calculated for [M + H]+: 256.2; found 256.2.  
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Compound 32: To a 100 mL 14/20 1 neck round bottom flask was added 350 mg (0.99 
mmol) of 35c, 750 mg (2.94 mmol) of 72, and 15 mL of DMF. The mixture was stirred at 100 °C 
for 5 h in an oil bath. The solvent was removed using a rotary evaporator. The crude was purified 
by C18 column chromatography using 0.1% TFA in H2O/MeOH mixture (gradient from 100:0 to 
10:90 (v/v) at a flow rate of 5 mL/min. Fractions containing product were combined and 
concentrated using a rotary evaporator to give 218 mg (21%) of 32 as a yellow TFA salt. 1H 
NMR (CD3OD-d4): δ 8.83 (d, J = 8.5, 1H), 8.62 (d, J = 8.7, 1H), 8.48 (d, J = 7.3, 1H), 8.05−8.03 
(m, 1H), 7.95−7.94 (d, J = 8.5, 1H), 7.68−7.63 (m, 2H), 4.52 (s, 2H), 3.66 (s, 2H), 3.56 (t, J = 
6.9, 4H), 3.40 (t, J = 6.6, 4H), 3.22 (q, J = 7.3, 2H), 1.83−1.70 (m, 4H), 1.32 (t, J = 7.3, 2H).  
HR-ESI-MS (m/z) calculated for [M + H]+: 573.3273; found 573.3275. HPLC (0.1% TFA in 
H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 12.9 min (97%). 
 
Compound 35: To a 25 mL 14/20 round bottom flask was added 0.5 g (1.7 mmol) of 12. 
The solid was suspended in 10 mL of anhydrous EtOH. To the resulting white suspension was 
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added 0.5 mL (3.6 mmol) of Et3N, resulting in a clear solution. To the reaction flask was added 
0.37 g (mmol) of 3-azido-propylamine 8c. The mixture was stirred at room temperature for 20 h. 
The white solid was obtained by vacuum filtration, washed with a mixture of EtOH and CH2Cl2 
(1/1, v/v) and with CH2Cl2. After drying under high vacuum, the solid was dissolved in 25 mL of 
MeOH containing 0.8 mL of concentrated HCl 37%. The resulting solution was stirred at room 
temperature for 2 h. The solvent was removed using a rotary evaporator. The solid was dried 
under high vacuum to give 0.41 g (74%) of 35 as a white HCl salt. 1H NMR (DMSO-d6): δ 
10.26−10.23 (m, 2H), 9.85 (s, 2H), 9.49 (s, 2H), 7.99 (s, 4H), 3.55−3.49 (m, 8H), 1.93 (quint, J = 
6.8, 4H). HR-ESI-MS (m/z) calculated for [M + H]+: 329.1951; found 329.1944. HPLC (0.1% 
TFA in H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 5.6 min (97%). 
 
Compound 74: To a 100 mL round bottom flask was added 0.57 g (1.9 mmol) of 12, and 
20 mL of anhydrous EtOH. To the white suspension was added 0.75 mL (5.4 mmol) of 
anhydrous Et3N at once. The reaction solution was stirred at room temperature, and became clear 
after 10 min. To the resulting solution was added 0.66 g (4.1 mmol) of N-Boc-ethylenediamine 
73. The mixture was stirred at room temperature for 3 h. The solvent was removed using a rotary 
evaporator. The crude was dissolved in 10 mL of TFA, and stirred at room temperature for 3 h. 
TFA was removed using a rotary evaporator. The crude was dissolved in 5 mL of MeOH, and 
suspended in 200 mL of acetone. The white solid was filtered, washed with acetone, and dried 
under high vacuum overnight to give 0.31 (23%) of 74 as a white TFA salt. 1H NMR (DMSO-
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d6): δ 10.30 (s, 2H), 9.99 (s, 2H), 9.63 (s, 2H), 8.38 (s, 6H), 8.08 (s, 4H), 3.78 (t, J = 5.9, 4H), 
3.19 (t, J = 5.8, 4H). 
 
Compound 36: To a 25 mL round bottom flask was added 0.24 g (0.34 mmol) of 74 and 5 
mL of DMF. To a separated vial was added 5 mL of CH2Cl2, 0.24 g (1.2 mmol) of DCC, and 
0.11 g (1.6 mmol) of propiolic acid 64. The solid was filtered, the filtrate was added to the 
reaction flask at once. The mixture was stirred at room temperature for 30 min. The reaction was 
concentrated using a rotary evaporator. The crude was purified by C18 column chromatography 
using a gradient mixture of H2O/MeOH from 100/0 to 90/10 (v/v) with 0.1% HCl 10M. 
Fractions containing products were combined and concentrated using a rotary evaporator to give 
0.13 g (90%) of 36 as a white HCl salt.  1H NMR (DMSO-d6): δ 10.14 (s, 2H), 9.86 (s, 2H), 9.50 
(s, 2H), 9.07 (t, J = 6.0, 2H), 7.96 (s, 4H), 4.23 (s, 2H), 3.57 (q, J = 5.5, 4H), 3.44 (q, J = 5.8, 
4H). LR-ESI-MS (m/z) calculated for [M + H]+: 353.2; found 353.3. 
 
Compound 37: To a 50 mL round bottom flask was added 0.06 g (0.3 mmol) of 7988 and 
10 mL of DMF. To a separated vial was added 10 mL of CH2Cl2, 0.12 g (0.06 mmol) of DCC, 
and 0.04 g (0.06 mmol) of propiolic acid 64. The resulting solution was added to the reaction 
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flask at once. The mixture was stirred at room temperature for 30 min. The reaction was 
concentrated using a rotary evaporator. The crude was purified by silica gel column 
chromatography using a gradient mixture of CH2Cl2/MeOH from 98/2 to 95/5 (v/v). Fractions 
containing products were combined and concentrated using a rotary evaporator to give 0.07 g 
(93%) of 37 as a brown solid.  1H NMR (DMSO-d6): δ 8.91 (d, J = 5.8, 1H), 7.92 (d, J = 8.2, 
1H), 7.84 (d, J = 8.8, 1H), 7,43 (t, J = 5.4, 1H), 7.05 (d, J = 7.9, 1H), 6.73 (d, J = 8.9, 1H), 
4.14−4.10 (m, 1H), 3.50−3.47 (m, 2H), 3.37−3.33 (m, overlap with H2O, 2H), 2.53 (s, 3H). HR-
ESI-MS (m/z) calculated for C14H15N4O: 255.1246; found 255.1238. 
 
Compound 38: To a 25 mL round bottom flask was added 990 mg (2.4 mmol) of 35a and 
10 mL DMF. To the resulting mixture was added 0.5 mL (3.6 mmol) of Et3N, and 310 mg (3.6 
mmol) of 2-azido-ethylamine 75. The mixture was stirred at 80 °C in an oil bath for 3 h. The 
solvent was removed using a rotary evaporator. The crude was purified by silica column 
chromatography using a gradient mixture of CH2Cl2/MeOH from 100/0 to 90/0 (v/v). Fractions 
containing product were combined and concentrated using a rotary evaporator. The crude was 
dissolved in 15 mL of CH2Cl2 and 15 mL of TFA. The mixture was stirred at room temperature 
for 3 h. The solvent was removed using a rotary evaporator. The crude was purified by silica 
column chromatography using a gradient mixture of CH2Cl2/MeOH from 100/0 to 75/25 (v/v). 
Fractions containing product were combined and concentrated using a rotary evaporator to give 
670 mg (47%) of 38 as a yellow TFA salt. 1H NMR (CD3OD-d4): δ 8.73 (dd, J = 8.7, 1.2, 1H), 
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8.56 (dd, J = 8.7, 0.5, 1H), 8.50 (dd, J = 7.5, 1.2, 1H), 8.05−8.02 (ddd, J = 8.3, 6.9, 1.3, 1H), 
7.95−7.93 (m, 1H), 7.68−7.63 (m, 2H), 4.35 (t, J = 5.7, 2H), 3.95 (t, J = 5.7, 2H), 3.64 (t, J = 6.7, 
2H), 3.10 (t, J = 7.5, 2H), 2.07 (quint, J = 7.1, 2H). HR-ESI-MS (m/z) calculated for [M + H]+: 
364.1886; found 364.1877. 
 
Compound 78: To a 100 mL round bottom flask containing 1.03g (3.7 mmol) of 76 was 
added 20 mL (300 mmol) of ethylenediamine 77. The mixture was refluxed at 120 °C for 10 h, 
and at room temperature overnight. To the reaction mixture was added 40 mL of DI water. The 
yellow solid was filtered, and washed with 20 mL of DI water. The yellow solid was suspended 
in 100 mL Et2O, sonicated for 1-2 min. The solid was filtered, washed with 50 mL Et2O to give 
0.74 g (66%) of 78 as a yellow solid. 1H NMR (CDCl3): δ 8.10 (d, J = 9.3, 1H), 8.05 (d, J = 2.1, 
1H). 7.98 (d, J = 9.3, 1H), 7.40 (dd, J = 9.4, 2.6, 1H), 7.35 (d, J = 2.7, 1H), 7.27 (dd, J = 9.2, 2.2, 
1H), 3.95 (s, 3H), 3.68 (m, 2H), 2.99 (m, 2H). 
 
Compound 39: To a 100 mL round bottom flask was added 0.35 g (1.2 mmol) of 78 and 
15 mL of CH2Cl2. To a separated vial was added 5 mL of CH2Cl2, 0.51 g (2.5 mmol) of DCC, 
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and 0.21 g (3.0 mmol) of propiolic acid 64. The solid was filtered, the filtrate was added to the 
reaction flask at once. The mixture was stirred at room temperature for 30 min. The reaction was 
concentrated using a rotary evaporator. The crude was purified by silica gel column 
chromatography using a gradient mixture of CH2Cl2/MeOH from 98/2 to 90/10 (v/v). Fractions 
containing products were combined and concentrated using a rotary evaporator to give 0.24 g 
(58%) of 39 as a yellow solid.  1H NMR (DMSO-d6): δ 9.10 (t, J = 4.9, 1H), 8.49 (d, J = 9.3, 
1H), 7.94 (d, J = 2.2, 1H), 7.87 (d, J = 9.3, 1H), 7.81 (s, 1H), 7.61 (dd, J = 9.3, 2.4, 1H), 7.44 
(dd, J = 9.4, 2.2, 1H), 4.20 (s, 1H), 4.08 (t, J = 6.5, 2H), 3.97 (s, 3H), 3.58 (q, J = 6.3, 2H). 13C 
NMR (CD3OD-d4): δ 158.05, 156.40, 155.62, 143.80, 140.04, 128.70, 128.15, 124.86, 124.25, 
121.23, 116.36, 112.55, 102.99, 77.72, 77.33, 56.68, 51.36, 40.89. LR-ESI-MS (m/z) calculated 
for [M + H]+: 354.1; found 354.2. 
Azide 40 was obtained from Julio Serrano. Azide-containing aminoglycosides 41−44 
were prepared using a published protocol.75 
Kanamycin 41: 1H NMR (D2O): δ 5.46−5.45 (m, 1H), 5.03 (m , 1H), 4.00−3.94 (m, 2H), 
3.91−3.81 (m, 3H), 3.74−3.67 (m, 2H), 3.64−3.27 (m, 10H), 3.15−3.09 (m, 1H), 2.50−2.45 (m, 
1H), 1.89−1.81 (q, J = 12.5, 1H) ; 13C NMR (D2O): δ 163.39−162.54 (q, TFA), 119.92−112.96 
(q, TFA), 100.83, 96.20, 84.08, 78.92, 72.45, 72.34, 71.60, 70.91, 70.85, 68.89, 68.26, 66.57, 
54.88, 50.82, 50.15, 47.71, 40.43, 30.37, 27.63.  
Apramycin 42: 1H NMR (D2O): δ 5.76 (d, J = 3.8, 1H), 5.55 (d, J = 3.9, 1H), 5.25 (d, J = 
8.5, 1H), 4.59 (t, J = 2.8, 1H), 4.15−4.11 (m, 1H), 4.00−3.92 (m, 3H), 3.82−3.76 (m, 3H), 
3.70−3.66 (m, 2H), 3.62−3.53 (m, 3H), 3.42−3.30 (m, 3H), 2.81 (s, 3H), 2.54−2.50 (m, 1H), 
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2.42−2.38 (m, 1H), 2.06 (q, J = 12.0, 1H), 1.89 (q, J = 12.6, 1H); HR-ESI-MS (m/z) calculated 
for [M + H]+: 565.2946, found 565.2946. 
Amikacin 43: 1H NMR (D2O): δ 5.47 (d, J = 3.9, 1H), 5.10 (d, J = 3.8, 1H), 4.22−4.18 (m, 
2H), 4.07−3.96 (m, 2H), 3.86−3.77 (m, 3H), 3.74−3.70 (m, 2H), 3.64−3.59 (m, 3H), 3.55−3.48 
(m, 3H), 3.40−3.30 (m, 3H), 3.14−3.10 (m, 3H), 2.19−2.08 (m, 2H), 1.94−1.86 (m, 1H), 1.75 (q, 
J = 12.6, 1H), 1.12 (t, J = 7.1, 1H); 13C NMR (D2O): δ 175.61, 163.42−162.56 (q, TFA), 
119.94−112.97 (q, TFA), 98.09, 95.90, 80.22, 79.54, 72.53, 72.42, 70.95, 70.87, 69.72, 68.88, 
68.12, 66.55, 66.13, 55.24, 50.50, 48.97, 47.96, 40.42, 37.08, 30.92, 30.23, 14.24; HR-ESI-MS 
(m/z) calculated for [M + H]+: 611.3000, found 611.2985. 
Neomycin 44: 1H NMR (D2O): δ 6.06 (d, J = 4.0, 1H), 5.37 (d, J = 2.3, 1H), 5.29 (d, J = 
1.8, 1H), 4.49−4.44 (m, 1H), 4.40−4.38 (m, 1H), 4.31−4.25 (m, 2H), 4.21 (t, J = 3.1, 1H), 4.08 
(dd, J = 10.4, 9, 1H), 4.01 (dd, J = 10.6, 8.9, 1H), 3.97−3.79 (m, 4H), 3.69−3.24 (m, 12H), 
2.50−2.45 (m, 1H), 1.90 (q, J = 12.7, 1H), 1.14 (t, J = 7.1, 2H); 13C NMR (D2O): δ 
163.32−162.48 (q, TFA), 119.95−112.99 (q, TFA), 110.86, 95.55, 95.13, 85.36, 79.54, 76.25, 
75.26, 73.44, 72.52, 70.72, 70.14, 69.87, 68.18, 67.77, 67.71, 66.10, 53.53, 51.54, 50.97, 49.90, 
48.58, 40.69, 40.32, 28.08, 14.24.; HR-ESI-MS (m/z) calculated for [M + H]+: 640.3266, found 
640.3251. 
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Compound 60: To a 100 mL 14/20 round bottom flask was added 210 mg (0.41 mmol) of 
27, 300 mg (0.40 mmol) of 25, and 13 mg (0.024 mmol) of TBTA. The solid was dissolved in 40 
mL of MeOH. The mixture was stirred at room temperature until a clear solution was obtained. 
To the reaction mixture was added 11 mg (0.044 mmol) of CuSO4.5H2O in 10 mL of water, and 
35 mg (0.18 mmol) of sodium ascorbate in 10 mL of water. The resulting mixture was stirred at 
room temperature for 2 h. The mixture was concentrated using a rotary evaporator. The crude 
was purified by silica gel column chromatography using a gradient mixture of acetone/NH4OH 
from 100/0 to 95/5 (v/v). Fractions containing product were combined, and concentrated using a 
rotary evaporator. The crude was dissolved in MeOH, and concentrated again to remove 
ammonium hydroxide. The yellow solid was dissolved in a mixture of 20 mL of MeOH and 0.5 
mL of TFA. The mixture was concentrated using a rotary evaporator to give 98 mg (15%) of 60 
as a yellow TFA salt. 1H NMR (CD3OD-d4): δ 8.66−8.63 (m, 2H), 8.49−8.45 (m, 3H), 8.41−8.38 
(m, 2H), 7.98−7.94 (m, 2H), 7.90−7.85 (m, 4H), 7.61−7.54 (m, 4H), 4.57 (t, J = 6.9, 2H), 4.19 
(q, J = 7.8, 4H), 3.61 (t, J = 6.5, 2H), 3.55 (t, J = 6.6, 4H), 3.44−3.41 (m, 4H), 2.11−1.97 (m, 
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8H), 1.80−1.70 (m, 6H). LR-ESI-MS (m/z) calculated for [M + H]+: 1041.5; found 521.3 ([M + 
2H]2+, 25%), 348.0 ([M + 3H]3+, 98%), 261.3 ([M + 4H]4+, 100%). HPLC (0.1% TFA in 
H2O/MeOH (1:1, v/v), flow rate = 3 mL/min): t = 15.4 min (96%).  
4.8.2 Synthesis of r(CUG)16 by In Vitro Transcription 
r(CUG)16 was prepared from the in vitro transcription of d(CTG)16 using a MEGAscript 
T7 transcription kit (Ambion). The DNA duplex containing d(CTG)16 and d(GAC)16 with a T7 
promoter was purchased from Integrated DNA Technology (Coralville, IA). The DNA solids 
were dissolved in DNase/RNase-free water. Their concentrations were determined using the 
Beer’s law with the absorbance at 260 nm measured on a Shimadzu UV-2501PC 
spectrophotometer (Kyoto, Japan), and the extinction coefficient at 25 °C provided from IDT. 
Structure of the DNA duplex: 5’-TTCTAATACGACTCACTATAGGG(CTG)16CCC-3’ 
3’-AAGATTATGCTGAGTGATATCCC(GAC)16GGG-5’ 
The DNA duplex solution containing 50 µM of d(CTG)16, 50 µM of d(GAC)16 was 
prepared in 1X transcription buffer. To a 500 µL minitube was added 35 µL of RNase-, DNase-
free water, 10 µL of 10X reaction buffer, 10 µL of ATP (100 mM), 10 µL of CTP (100 mM), 10 
µL of GTP (100 mM), 10 µL of UTP (100 mM), 5 µL of DNA solution, and 10 µL of T7 enzyme 
mix. The mixture was mixed by inverting the tube two times, and incubated at 37 °C in a water 
bath overnight. To degrade the excess DNA, the resulting solution was mixed with 5 µL of 
TURBO DNase (2U/µL), and incubated at 37 °C for 15 min. The protein was removed by 
phenol-chloroform extraction. To the reaction mixture was added 575 µL DNase-, RNase-free 
water and 75 µL of ammonium acetate solution. The solution was extracted with 750 µL of 
phenol:chloroform (5:1, v/v) solution. The aqueous layer was transferred to a 2 mL minitube, 
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and extracted with 750 µL chloroform:isoamyl alcohol (24:1, v/v) solution. The aqueous layer 
was transferred to two 2 mL minitubes. The unpurified RNA was recovered by ethanol 
precipitation. To each 2 mL minitube was added 1200 µL of cold absolute ethanol. The resulting 
solutions were incubated at -80 °C for 2 h. The tubes were centrifuged at 13000 rpm for 15 min 
at 4 °C. The solvent was removed to give the RNA pellet. RNA pellets were purified by Urea gel 
20% using a UreaGel System (National Diagnostics). The gel was run at 300 V for 60 min. The 
gel was stained with ethidium bromide solution for 10 min, and washed with Milli-Q water for 
10 min. The gel was visualized under a UV shadowing. The r(CUG)16 band was isolated, cut into 
small pieces, and soaked in 500 µL of DNase-, RNase-free water at 37 °C for 2 h. The solution 
was collected. The RNA was recovered by ethanol precipitation. RNA pellets were dissolved in 
RNA storage buffer, the concentration was determined by UV-Vis. 
Other DNA/RNA sequences were purchased from Integrated DNA Technology 
(Coralville, IA). DNA samples were stored in DNase/RNase-free water, whereas RNA was 
dissolved in RNA storage buffer containing 1 mM sodium citrate pH 6.4 (Ambion® #AM7001).  
4.8.3 Selection Experiments Using DNA and RNA 
The selection experiment containing compounds 6a−c, 23−32, 35, 38, and 45−59. 
Structures of r(CUG)16, 24m-DNA, d(CTG)16-d(GAC)16, r(CCUG)8 were shown in Figure 24. 
The structure of d(CTG)16 used in this experiment is: 5’-
TTCTAATACGACTCACTATAGGG(CTG)16CCC-3’. 24m-DNA, d(CTG)16-d(GAC)16, 
r(CCUG)8 were purchased from Integrated DNA Technology (Coralville, IA); yeast tRNA was 
purchased from Invitrogen (Carlsbad, CA); r(CUG)16 was obtained the in vitro transcription as 
described above. The DNA and RNA solids were dissolved in DNase/RNase-free water, and the 
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RNA storage buffer, respectively. Their concentrations were determined using the Beer’s law 
with the absorbance at 260 nm measured on a Shimadzu UV-2501PC spectrophotometer (Kyoto, 
Japan), and the extinction coefficient at 25 °C provided from IDT. 
 The DNA/RNA solutions (400 μL, 12.5 μM DNA/RNA, 2 mM Tris-HCl pH 7.0, 2 mM 
KCl, 2 mM MgCl2, and 1 mM CaCl2) were heated at 95 °C for 5 min, and cooled slowly to room 
temperature for 1 h. To the DNA/RNA solutions were added ligands to the final concentration of 
25 μM each compound. The DNA/RNA solutions were shaked at 37 °C over a week. Everyday, 
10 μL of the RNA-templated reaction was withdrawn, and mixed with 10 μL of Urea 8 M, and 1 
μL of RNase A (10 mg/mL). Similarly, 10 μL of the DNA-templated reaction was withdrawn 
daily, and mixed with 1 μL of TURBO-DNase A 10X. The resulting samples were incubated at 
37 °C in a water bath for 20 min, then analyzed by MALDI-MS technicians in the Mass 
Spectrometry Laboratory, UIUC. The reaction without DNA/RNA was conducted using the 
similar procedure. The experiment was triplicated. 
The selection experiment containing compounds 6a−c, 24, 25, 27, and 35−59. 
Structures of r(CUG)16, d(CTG)16, 24m-DNA, r(CCCCGG)3, and HIV-1 FS RNA were shown in 
Figure 24. The structure of r(CCUG)12 used in this experiment is: 5’-GGG(CCUG)12CCC-3’. 
d(CTG)16, 24m-DNA and HIV-1 FS RNA were purchased from Integrated DNA Technology 
(Coralville, IA); yeast tRNA was purchased from Invitrogen (Carlsbad, CA); r(CCCCGG)3 was 
obtained from Prof. Keith T. Gagnon, Southern Illinois University.  
Generally, the selection experiment was conducted as described previously. For the 
samples containing r(CUG)16, r(CCUG)12, r(CCCCGG)3, and tRNA: 10 µL of the reaction was 
mixed with 10 µL of Urea 8 M, and 2.5 µL of RNase A (10 mg/mL). Similarly, 10 µL of the 
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reaction using d(CTG)16 and 24m-DNA was withdrawn daily, and mixed with 2.5 µL of 
TURBO-DNase A 10X. The resulting samples were incubated at 37 °C in a water bath for 30 
min, then analyzed by MALDI-MS. For the HIV-1 FS RNA templated reaction: 5 µL of the 
reaction was mixed with 5 µL of Urea 8 M, and 2.5 µL of RNase A (10 mg/mL). The mixture 
was incubated at 37 °C for 60 min. 
Preparation of MALDI-MS samples: 1 µL of the r(CUG)16, r(CCUG)12, r(CCCCGG)3, 
tRNA, d(CTG)16 and 24m-DNA samples or 2 µL of the HIV-1 FS RNA sample was mixed with 
10 µL of the DHB matrix solution (25 mg in 1 mL of MeOH) or 10 µL of the CHCA matrix 
solution (10 mg in 1 mL of H2O/acetone (1/1, v/v) with 0.1% TFA). The resulting solution (1 µL) 
was spotted on a MALDI-MS plate and dried slowly. The MS was obtained using a positive 
mode. 
Monitoring r(CUG)16-templated click reaction of 25 and 27 by HPLC. RNA-
templated reactions (200 μL, 100 μM each compound, 25 μM r(CUG)16, 2 mM Tris-HCl pH 7.0, 
2 mM KCl, 2 mM MgCl2, and 1 mM CaCl2) were incubated at 37 °C over a week. Everyday, 15 
μL of reaction was withdrawn, mixed with 15 μL of Urea 8 M, and 2 μL of RNase A (10 
mg/mL). The resulting sample was incubated at 37 °C for 20 min. The sample was mixed with 
68 μL of 28 (40 μM), analyzed by HPLC (0.1% TFA in H2O/MeOH (1:1, v/v), flow rate = 3 
mL/min). A parallel experiment without RNA was conducted using the similar procedure. 
4.8.4 Biological Activities of the Click Product 
In vitro transcription inhibition. Briefly, for in vitro transcription inhibition 
experiments, ligands at desired concentrations were incubated with 15 ng of linearized d(CTG)74 
plasmid in 1X T7 transcription buffer (80 mM Tris pH 8.3, 10 mM MgCl2, 2 mM spermine, 
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0.1% Triton-X, 10 mM NaCl) containing 0.5 mM of rATP, rCTP, rGTP, and rUTP (Promega) at 
37 °C. After 3.5 h, T7 polymerase (New England Biolab) was added to the final concentration of 
0.5 U, and the transcription reaction was allowed to process for 1.5 h. The reaction was quenched 
by adding 6.5 µL of Urea 8 M, 2 µL of denaturing dye (95% formamide, 5 mM EDTA, 0.025% 
xylene cyanol and bromophenol blue), and 1.5 µL of HIV-1 FS RNA (10 µM) as an internal 
standard and heating to 95 °C for 5 min. The solution (15 µL) was loaded on a 8% denaturing 
PAGE gel and the RNA was detected by EtBr post-staining. Bands were quantified using the 
ImageJ (NIH). The intensity ratio of r(CUG)74/HIV FS RNA from ligand-treated sample was 
compared with that from the untreated sample, providing the percentage of the transcription 
inhibition of ligand.  
Inhibition of MBNL1-r(CUG)12 by EMSA. The IC50 and KI values were determined as 
described in chapter 3, with [MBNL1]total = 70 nM. 
 
 
Figure 36. Determination of the binding constant of MBNL1-r(CUG)12 by EMSA. Left: A 
representative gel from the EMSA experiments. The concentration of MBNL1 was diluted by a factor of 
3 from 2.34 µM to 1.47 pM. Right: Plot of normalized RNA fraction bound vs. concentration of 
MBNL1. The standard deviation was obtained from three independent experiments. 
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Determination of binding affinity by fluorescence binding experiments. The 
fluorescence binding experiment was carried out using a Horiba Jobin Yvon fluorometer with a 1 
mL cell (0.5 cm wide) at 25 °C. The RNA sample (300 µM r(CUG)16, 20 mM MOPS pH 7.0, 
and 300 mM NaCl) were heated in a water bath at 95 °C for 5 min, then allowed to cool slowly 
to room temperature. The ligand solution (400 µL, 0.2 µM compound 25, 20 mM MOPS pH 7.0, 
and 300 mM NaCl) was excited at 438 nm (excitation slit of 5 nm). Emission was recorded 
between 446−546 nm (emission slit of 5 nm), monitoring at 468 nm for 25. To the ligand 
solution was added the freshly annealed r(CUG)16 as 1 µL injections via pipette. The sample was 
then allowed to equilibrate for 15 min and the fluorescence emission was recorded. The titration 
was performed until the fluorescence change was no longer evident. The normalized 
fluorescence intensity at 468 nm versus the concentration of RNA was plotted and fit using the 
one binding site model with a Hill slope in Prism.  
Similarly, the ligand solution for 60 (400 µL, 0.2 µM compound 60, 20 mM MOPS pH 
7.0, and 300 mM NaCl) and the RNA solution (30 µM r(CUG)16, 20 mM MOPS pH 7.0, and 300 
mM NaCl) were prepared. The ligand solution was excited at 438 nm, emission was recorded 
between 446−546 nm, monitoring at 513 nm. 
For the binding experiment with monomer 25 and d(CTG)16: The DNA sample (40 µM 
d(CTG)16, 20 mM MOPS pH 7.0, and 300 mM NaCl) and the ligand solution (400 µL, 0.2 µM 
compound 25 20 mM MOPS pH 7.0, and 300 mM NaCl) were prepared. For the binding 
experiment with 60 and d(CTG)16: The DNA sample (2 µM d(CTG)16, 20 mM MOPS pH 7.0, 
and 300 mM NaCl) and the ligand solution (400 µL, 0.2 µM compound 60, 20 mM MOPS pH 
7.0, and 300 mM NaCl) were prepared. The experiment was conducted as described above. 
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